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ABSTRACT 
 
The most abundant biological thiols, homocysteine (Hcy), cysteine (Cys) and 
glutathione (GSH) have been the subject of intense research due to their association with 
a wide range of diseases. They play a key role in maintaining the redox status of 
biological systems. Selective detection methods for these thiols are challenging due to 
their similar structures and properties. Current commercially available detection methods 
use separations, fragile and expensive enzymatic or immunogenic materials and complex 
instrumentation. This has led to a global effort towards developing simple and 
inexpensive optical probes and indicators selective for specific biological thiols. 
Highly selective chemical probes and simple methods for detection and potential 
quantification of Hcy and GSH in their natural biological media have been developed. 
These indicators and methods are relatively simple and inexpensive for potential 
application at point of care. The selective detection of Hcy using novel asymmetric 
viologen chemical probes at room temperature is described as well as the use of 
commercially available materials under photochemical conditions. These probes respond 
linearly proportional to increasing Hcy concentrations, potentially enabling the 
monitoring of Hcy levels in human plasma. Additionally, new methods for the selective 
determination of GSH in human plasma, as well as its quantitation in whole blood 
deposited on filter paper (dried blood spots), is also presented herein. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background and significance of homocysteine (Hcy) 
1.1.1 Structures and composition of biological thiols 
Biothiols such as homocysteine (Hcy), glutathione (GSH) and cysteine (Cys), 
(structures shown in Figure 1.1) play significant roles in regulating various biological 
processes. GSH, a tripeptide γ-glutamyl-cysteinyl-glycine is the major non-protein 
intracellular thiol which apart from being an important antioxidant, also regulates cellular 
functions such as gene expression, cell proliferation and apoptosis.
1-3
  GSH 
concentrations in cells range from 1–10 mM whereas plasma levels range from 1–6 
μM.1,4-7 Cys is the most abundant low-molecular-weight thiol in plasma and plays a 
fundamental role in protein synthesis, cell metabolism and detoxification.
8
 It is a 
precursor of GSH and its structure closely resembles that of Hcy. Healthy levels of Cys 
range from 135–300 μM and its abnormal levels are associated with various disease states 
such as liver damage, edema and skin lesions.
7,9-11
  
Hcy is a metabolic intermediate derived from the essential amino acid methionine 
in the biosynthesis of Cys.
12
 Structurally, Hcy differ from Cys by a single methylene 
group (Figure 1.1) which makes their individual determination very challenging. It exists 
in various forms in plasma with the most dominant one being the protein bound 
accounting for 70-80% of total Hcy, followed by the free oxidized form (non-protein-
bound disulfides) constituting 20% and finally  free, reduced Hcy making up less than 
2 
 
1% of the total pool.
7
 Plasma total homocysteine (tHcy) refers to the sum of all the three 
forms (all circulating disulfides and reduced Hcy).  
Normal plasma tHcy concentrations range from 5–15 μM. At elevated levels, a 
condition known as hyperhomocysteinemia occurs that is an independent risk factor for 
several major pathologies such as cardiovascular disease (CVD), dementia, osteoporosis 
and Alzheimer’s disease.13-15 Hyperhomocysteinemia is classified into three categories 
including moderate (15–30 μM), intermediate (30–100 μM) and severe (>100 μM).7,16 
Due to the relationship between hyperhomocysteinemia and lower methionine synthase 
activity and folate deficiency, it has been proposed that folate therapy may be useful for 
for hyperhomocysteinemia-related disorders.
17
 
 
Figure 1.1. Structures of selected biological thiols. 
 
1.1.2 Significance of Hcy to public health 
Hcy plays a critical role in methionine and folate metabolism. It is a metabolic 
intermediate that participates in two pathways, the re-methylation (methionine cycle) and 
transsulfuration (folate cycle, Figure 1.2).
18,19
 In the re-methylation pathway, Hcy 
3 
 
receives a methyl group from 5-methyltetrahydrofolate (most common in cells and 
tissues) or betaine and is reconverted to methionine, which is fundamental to biochemical 
processes such as protein and nucleic acid synthesis. In the transsulfuration pathway, Hcy 
is converted to Cys through cystathionine in a reaction involving serine and catalyzed by 
a vitamin B6 dependent enzyme, cystathionine-β-synthase. This pathway is irreversible 
indicating the inability of Cys to serve as a precursor for methionine. Most Cys formed is 
in turn converted to the tripeptide GSH. 
 
Figure 1.2. Pathways for the metabolism of Hcy.
18,19
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Elevated plasma levels of Hcy 
20,21
 can be caused by metabolic defects in the two 
pathways or deficiencies of enzymes and cofactors required in these pathways.  
Hyperhomocysteinemia can be caused by the impaired synthesis of 5-
methyltetrahydrofolate due to the deficiency of folate or a defect in 
methylenetetrahydrofolate reductase (MTHFR).
12
 In these cases, Hcy meant for re-
methylation would be channeled to the transsulfuration pathway thereby decreasing the 
intracellular s-adenosylmethionine (SAM) concentration as well as overburdening the 
transsulfuration system with excess Hcy. The additional Hcy coupled with lower 
concentrations of SAM (not sufficient to activate cystathionine synthesis) damage the 
transsulfuration pathway. Eventually, Hcy accumulates in cells and is consequently 
exported into the blood causing hyperhomocysteinemia.
12,19,22
 
Another cause of hyperhomocysteinemia is a defect in cystathionine-β-synthase 
that impairs the transsulfuration pathway via the diversion of Hcy towards the 
remethylation pathway. This increases the rate at which methionine is synthesized 
leading to a rise in the level of intracellular SAM. The level of SAM can reach a point 
where it causes feedback inhibition of MTHFR, thus blocking the re-methylation process. 
This leads to severe hyperhomocysteinemia because both pathways would have been 
impaired.
12,22
 Abnormalities in the enzyme cystathionine-β-synthase also cause 
homocystinuria which is an autosomal recessive disorder characterized by ocular lens 
dislocation, mental retardation and aggressive vascular disease, in particular venous 
thromboembolism.
18
 Other factors which have been reported to cause 
hyperhomocysteinemia include environmental toxins as well as poor nutrition and 
5 
 
lifestyle. For example, cigarette smoking, a high intake of alcohol and caffeine are 
associated with increased Hcy levels.
23
 Hcy concentrations rise in diseases such as 
cancer, hypothyroidism, inflammatory bowel and end-stage renal disease.
20,24,25
 Hcy 
levels rise with age, and women generally have lower levels than men but the 
concentrations rise after menopause.
26,27
  
Several studies have been published showing an association between elevated 
levels of Hcy and CVD. A strong link between plasma Hcy and CVD mortality has been 
established in an early study by the World Health Organization (WHO).
28
 Nygard, et al., 
in their 2001 study, discovered that the cardiovascular related mortality ratios doubled 
when Hcy levels were twice as high.
29
 Meta-analyses of both prospective and genetic 
studies demonstrated that there is a significant association between Hcy levels and CVD. 
In these studies it was predicted that lowering tHcy by 3 µmol/L (by increasing folic acid 
intake) would reduce the risk of heart disease by 11–16%, thrombosis by 25% and stroke 
by 19–24%.30,31 A recent study by Bertoia, et al., found that higher Hcy levels were 
positively associated with a risk of peripheral artery disease in men.
32
 It has been reported 
that each 5 µmol/L increase in Hcy level increases the risk of coronary heart disease 
(CHD) events by approximately 20%, independently from traditional CHD risk factors. 
In the Multi-Ethnic Study of Atherosclerosis (MESA), it was found that higher Hcy 
levels were significantly associated with a higher incidence of CVD and CHD.
33
  
Meta-analysis genetic studies have also given further evidence showing the casual 
relationship between elevated tHcy and CVD. The homozygous mutant for MTHFR 
C677T polymorphism which affects about 10% of individuals worldwide results in 
6 
 
impaired folate metabolism and elevated tHcy levels.
34
  Three meta-analyses involving 
over 25,000 cases examined the impact of this genetic variant (homozygous MTHFR 
polymorphism) on heart disease risk and found that the risk was higher in individuals 
with polymorphism compared to those without the polymorphism by about 14-21%.
30,3536
  
In another study, the relationship between MTHFR polymorphism and the 
severity of coronary artery disease in patients undergoing coronary artery bypass surgery 
showed that Hcy levels were significantly higher in patients with coronary artery disease 
than in control subjects.
37
  
Hcy has also been associated with neural tube defects, increased incidence of 
dementia, inflammatory bowel disease and osteoporosis.
38,39
  In addition, elevated Hcy 
can be used to diagnose and follow the progression of cardiovascular disease in cases 
where classical risk factors such as hypertension, diabetes and hyperlipidemia are absent.  
Therefore a compelling case can be made for detecting and treating 
hyperhomocysteinemia in patients with a history of premature cardiovascular disease, 
stroke, or venous thromboembolism.
40
   
 
1.2 Hcy controversy 
Although significant research has shown that Hcy is a risk factor at even modestly 
elevated levels,
41
 the role of Hcy in cardiovascular diseases is not clear and has been 
debated for decades as to whether it is just a biomarker or actually a risk factor. However, 
according to the 2006 government study published in Circulation by Yang, Q., et al., 
7 
 
strong evidence was provided showing the association between Hcy and cardiovascular 
risk.
42
  They found that folate fortification (for lowering Hcy levels) significantly reduced 
deaths from strokes and heart attacks. More recent studies confirmed that homocysteine 
is a strong, independent CVD predictor.
43
 More so, Wang et al., in their meta-analysis on 
the efficacy of folic acid supplementation in stroke prevention concluded that folic acid 
supplementation can effectively prevent stroke in populations with no or partial folic acid 
fortification.
44
  
On the other hand, a meta-analysis of the Cochrane Database of Systematic 
Reviews published by Carvajal et al., 2009 indicated that Hcy lowering therapy did not 
reduce the risk of myocardial infarction and stroke.
45
 In another recent study, it was 
concluded that folic acid based homocysteine lowering does not reduce cardiovascular 
events in people with kidney disease.
46
 Numerous secondary intervention trials involving 
lowering Hcy levels by vitamin supplementation have been performed recently but none 
afforded conclusive evidence of generally improved CVD outcomes.
47,4849,50
 However, it 
should not be assumed that no relationship exists because such studies conflict with a 
massive body of published evidence clearly showing that Hcy is toxic at even modestly 
elevated levels.
47,51
 They contradict other clinical trials (e.g., the NIHLB’s Framingham 
study) in the broader CVD biomarker field that view Hcy monitoring as useful, for 
instance, in clinical situations wherein CVD patients are asymptomatic and/or traditional 
risk factors are not elevated or had been already well-controlled.
52
  
Several explanations for the intriguing and conflicting clinical trial outcomes have 
been reported and these include: 
47,53
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(i) homocysteine-lowering trials could have been underpowered by the duration 
of follow-up  which has been too short as shown in the meta-analysis of the 
effect of B vitamins on stroke.
54
 The result of this study was a full absence of 
any effect in the short-term but a statistically significant 29% reduction in the 
studies with at least 36 months of follow-up; 
 
(ii) vitamin supplements given to lower Hcy levels have themselves been shown 
to exacerbate CVD, and therefore negated any benefits of Hcy lowering;  
 
(iii) cohorts recruited all had advanced atherosclerotic disease and thus Hcy had 
apparently already done its major damage in mediating progression, rendering 
lowering Hcy interventions too late;  
 
(iv) since elevated Hcy levels can arise from and impact a highly complex set of 
pathogenic mechanisms, more specifically targeted mechanism- and/or 
patient-specific interventions than relatively simple vitamin supplementation 
may be needed to effectively manage CVD via targeting Hcy levels;   
 
(v) interpretation of the results from these large vitamin trials may have been 
incorrect due to statin/aspirin therapy, which was applied along with the 
vitamin and folic acid fortification. 
 
9 
 
Despite this controversy, the consistency in published evidence showing a strong 
relation between hyperhomosysteinemia and cardiovascular related diseases renders Hcy 
determination of clinical significance.
47
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CHAPTER 2: HCY DETECTION METHODS 
 
2.1 Current clinical methods 
The clinical relevance of Hcy as a diagnostic risk factor for CVD has justified the 
need to develop rapid, precise, and accurate techniques for detecting and quantifying 
tHcy. Currently, there are three main tHcy testing methods that are used in clinical 
laboratories including chromatographic (analytical HPLC with a derivatization step, gas 
chromatography/mass spectrometry (GC-MS)), immunoassays and enzymatic assays. 
38,41,55,56
  While the HPLC method has high precision and sensitivity, it often requires 
skilled staff, is labor intensive and throughput may be low.
38,57
 The need for 
derivatization introduces additional sample processing steps hence it’s not the method of 
choice in major clinical laboratories. GC-MS uses complex instrumentation that is not 
typically applied at point-of-care and requires tedious procedures not suitable for routine 
diagnostic applications.  
Immunoassays and enzymatic methods use antibodies and biomolecules that are 
relatively expensive and fragile; therefore, careful attention to storage conditions is 
required.
58
 Despite those shortcomings, the enzyme cycling assay is becoming the 
preferred method for clinical laboratories involved in routine screening applications over 
the immunoassays and chromatographic approaches because it uses less reagents, does 
not require sample pre-treatment and offers high throughput.
58,59
 Hcy assay interference 
from hemolysis, icterus, and lipemia has been reported with the hemoglobin interference 
being the most prevalent.
60
 Large differences between the methods used and the different 
11 
 
testing laboratories have been reported creating the need for more standardization of tHcy 
testing methods.
55,61,62
 
 
2.2 Optical methods 
Optical techniques including colorimetric or fluorescence and luminescent have 
received increased attention over other analytical methods because they offer a number of 
advantages such as operational simplicity, low cost, suitability for monitoring 
intracellular analytes and high sensitivity.
63,64
 A wide variety of useful optical detection 
probes for biological thiols based on different mechanisms has been reported.
65-67
 Most 
have no specificity for Hcy over other structurally related analytes such as Cys and GSH. 
Selective determination of plasma tHcy levels (normal, 5–15 μM) is further complicated 
by the higher levels of Cys (135–300 μM) almost 20 times that of Hcy and comparable 
levels of GSH (1–6 μM).6,7,10,16  
 
2.2.1 Hcy/Cys selective probes over GSH 
Most probes can distinguish Cys/Hcy from GSH and recent examples include a 
commercially available chromophore, 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) 
reported by Niu and co-workers (Figure 2.1).
68
 The proposed mechanism involves 
intramolecular displacement of chloride by thiolate followed by replacement of the 
thiolate with the amino groups of Cys/Hcy, but not GSH to form amino-substituted 
12 
 
products which show strong fluorescence compared to that exhibited by the sulfur-
substituted product for GSH. 
 
Figure 2.1. Substitution reaction of NBD-Cl (4) with aminothiols.
68
 
 
Goswami et al., developed a turn on excited-state intramolecular proton transfer 
(ESIPT) probe, 5(benzothiazol-2-yl)-4-hydroxyisophthalaldehyde (BHI) for rapid and 
ratiometric fluorogenic detection of Hcy and Cys over other amino acids (Figure 2.2).
69
 
This probe, however cannot discriminate between Hcy and Cys. 
 
 
Figure 2.2. Reaction of 7 with Hcy/Cys.
69
 
 
 
13 
 
2.2.2 Hcy selective probes  
Though some chemosensors or chemodosimeters that selectively respond to Hcy 
over Cys and other thiols have been reported, they are typically tested at equimolar, 
rather than more natural ca. 20-fold excess Cys concentrations.
70-72
 A phosphorescent 
sensor based on the iridium(III) complex was reported by Chen and co-workers to be 
selective for Hcy over Cys and GSH (Figure 2.3). With this probe phosphorescence 
emission is enhanced in the presence of Hcy and quenched in the case of Cys. Thus, the 
aldehyde group on this probe reacts with both Hcy and Cys forming thiazinane and 
thiazolidine adducts respectively. However, the basis for Hcy selectivity was reported to 
be a result of a photoinduced electron-transfer process on the thiazolidine (Cys adduct). 
While it’s a promising probe, higher concentrations of Hcy (400 µM) were used, by far 
more than physiological levels. A higher percentage (90%) of the organic solvent 
(DMSO) was used which would affect the accurate quantitation of analyte in biological 
samples.
73
 
  
Figure 2.3. Possible recognition mechanism of 9 with Hcy.
70
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Yu et al., developed a fluorescent mesoporous silica nanoparticle (MSN) sensor 
with an anthracene nitroolefin as well as the polyethylene glycol (PEG) covalently 
immobilized on the particle surface.
71
 While all thiols react with the nitroolefin moiety in 
a Michael addition reaction restoring fluorescence of the anthracene (Figure 2.4), the 
basis for Hcy selectivity was the PEG molecules that served as a selective barrier 
blocking other thiols from diffusing into the nanopores. The reported selectivity was 
achieved at equimolar amounts of thiols (50 µM), 3 times more than plasma levels of 
tHcy and 6 times less than Cys plasma levels indicating that at physiological levels, Cys 
would become a major interference. Moreover, at 50 µM, it was evident that Cys showed 
responses that were higher than the control.  
 
Figure 2.4. Proposed mechanism for Hcy selectivity by the Mesoporous silica nanoparticle - based sensor.
71
 
 
Recently, Peng and co-workers reported a redox-based fluorescent probe for 
selective determination of Hcy (Figure 2.5).
72
 The proposed reaction mechanism involves 
the oxidation of Hcy by a dansyl azide-2 (DN-2) probe selectively over Cys because of 
the favorable formation of cyclic five-membered ring intermediate as opposed to the 
strained four membered ring for Cys. The reported selectivity was obtained using 
equimolar amounts of 100 µM for both Hcy and Cys that do not represent the 
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physiological levels. Additionally, at 200 µM Cys was found to be interfering with Hcy 
determination, elevating fluorescence response of probe to Hcy by ~ 40%.   
 
Figure 2.5. Sensing reaction of 13 with Hcy.
72
 
 
Our group developed a visual detection method for Hcy and Cys with aldehyde-
bearing fluorophores based upon the well-known reaction of these thiols to form 
heterocyclic thiazolidines and thiazinanes.
74
 Fluorescence quenching of fluorescein 
aldehyde probes following the formation of thiazolidine/thiazinane heterocycles with Cys 
and Hcy was observed under the basic conditions investigated. We further improved this 
method recently to selectively detect Hcy over Cys by tuning pH and excitation 
wavelength.
75
 At lower pH (5.5-6) and longer wavelength excitations (495 nm), 
fluorescence enhancement of >5 fold for Hcy over Cys is achieved through inhibition of 
photo induced electron transfer (PET) as the thiazolidine/thiazinane heterocycles formed 
become protonated (Figure 2.6).  
16 
 
 
Figure 2.6. Mechanism of signal transduction in generic aldehyde-bearing amino thiol probes. (a) PET-
based fluorescence quenching following reaction of Cys/Hcy with the aldehyde group. (b) PET inhibition 
through hydrogen bonding between the amine-containing heterocycle and adjacent groups. (c) PET 
inhibition through protonation of the amine-containing heterocycle.
75
 
 
2.2.3 Hcy selective probes based on free radical chemistry 
Biothiols are oxidized to thiyl radicals via three main routes including reaction 
with carbon centered radicals, with reactive oxygen species (ROS) and through 
enzymatic oxidation by peroxidases.
76
 Two important reactions of thiyl radicals include 
the reaction with the thiolate to form a reducing disulfide radical anion (Equation 1) and 
the formation of a reducing alpha-amino carbon-centered radical (Equation 2). 
 
 
17 
 
Rate constants of Eq 2 have been reported to be generally of the order of 10
8
 M
–1
·s
–1
 but 
the reverse reaction is much slower.
76,77
 If the hydrogen donation reaction in equation 2, 
known as the “repair reaction”, proceeds intermolecularly, it can promote the “repair” of 
carbon-centered free radical-containing biomolecules such as carbohydrate-based 
radicals of DNA.
76
 Following the report by Neta and co-workers of the α-amino alkyl 
radical of Cys, Sjoberg et al. and Zhao et al. extended the work and reported the 
formation of reducing α-amino alkyl radicals of GSH and Hcy through intramolecular 
rearrangement of their respective thiyl radicals.
78-80
  
Importantly, Zhao and co-workers reported that intramolecular formation of the 
captodatively-stabilized α-amino alkyl radical in Hcy should be favorable. This was 
attributed to a kinetically-favored intramolecular hydrogen atom transfer (HAT) 
mechanism, involving the favored formation of a 5-membered ring in the transition state, 
as opposed to 4- and 9-membered ring configurations for Cys and GSH, respectively 
(Figure 2.7). Alpha-amino acid carbon radicals are well-known strong reductants. 
Captodative stabilization of the alpha-radical renders the alpha C-H bond weaker than the 
S-H bond by approximately 4 Kcal/mol. 
18 
 
 
Figure 2.7 Kinetically favored HAT reaction for Hcy. The rate constant for the kinetically-favored sulfur-
to-carbon-H atom transfer for Hcy is >10
5 
s
-1
.
80
 
 
In their study, Zhao and co-workers used the azide radical to oxidize thiols and 
the formation of reducing radicals was monitored via UV-Vis absorption spectra of the 
reduced methyl viologen radical cation (MV
•+
). Under the highly basic conditions (pH 
10.5) investigated by Zhao et al., no colorimetric selectivity between GSH, Cys and Hcy 
was observed. This was due to the presence of significant amounts of thiolate anion 
promoting the formation of a reducing disulfide radical anion (equation 1) that also reacts 
with methyl viologen (MV
2+
) independently of the HAT mechanism. Conversely, neutral 
conditions investigated by us diminish thiolate formation such that there is only a 
relatively small percentage of deprotonated thiol. Thus, it was reasoned by our group, that 
the Hcy-favored HAT process occurring in equation 2 should be more predominant than 
interfering disulfide radical anion formation at physiological pH. This enabled us to 
selectively detect Hcy in human blood plasma without any interference from Cys, GSH 
and other amino acids in 2004.
74,81
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In this colorimetric method remarkable visual color changes were later obtained 
in human blood plasma without any deproteinization using commercially available MV
2+
 
at neutral pH and reflux conditions (Figure 2.8). The mechanism involves the reduction 
of MV
2+
 by the Hcy-α-amino carbon centered radical to its corresponding radical cation 
which is responsible for the blue color (Figure 2.9). A protocol for visual detection of 
Hcy was developed based on this method wherein the Hcy thiyl radical is generated by 
heat.
82
  No washing steps, biological reagents or sample pre-processing steps apart from 
disulfide reduction are needed in this method.  
 
 
Figure 2.8. Selective detection of Hcy in human plasma spiked with 4.0 mM of Cys, Hcy and GSH, 8.0 
mM MV
2+
, 0.5 mM Tris buffer pH 7.5, and refluxed for 5 min. Inset shows samples before heating. 
*Adapted with permission from the Journal of the American Chemical Society, 2005, Volume 127, pages 
15949-15958; Weihua Wang, Oleksandr Rusin, Xiangyang Xu, Kyu Kwang Kim, Jorge O. Escobedo, Sayo 
O. Fakayode, Kristin A. Fletcher, Mark Lowry, Corin M. Schowalter, Candace M. Lawrence, Frank R. 
Fronczek, Isiah M. Warner, and Robert M. Strongin; Detection of Homocysteine and Cysteine. Copyright 
2005 American Chemical Society. 
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Figure 2.9. Reaction mechanism for selective detection of Hcy using MV
2+
 at neutral pH
74
. (a) Hydrogen 
atom transfer (HAT) (b) reduction of MV
2+ 
(c) iminium formation. 
 
While significant progress was made with MV
2+
, the probe was only applied to 
non-reduced plasma and had not been tested in real samples. Human plasma had been 
spiked with commercial thiol samples. To detect total Hcy (tHcy) a new step had to be 
introduced, reduction step, to convert all oxidized Hcy species into the reduced form 
since almost 99% of Hcy is in oxidized disulfide form. Figure 2.10 shows a summary of 
an improved thermal method that I developed which incorporated the reduction step.  
 
 
 
Figure 2.10. Improved thermal method for detection of Hcy. 
 
I investigated this method using non-deproteinized human serum calibration 
standards (NIST SRM 1955), and successfully distinguished micromolar concentration 
differences (3.79, 6.13, 13.4 and 38.73 M) of tHcy visually using MV2+ (Figure 2.11).66 
Disulfide Reduction 
(TCEP) 
Addition of buffer 
& MV
2+
 
  Reflux 
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As tHcy concentration increased, the color became successively darker and darker as 
shown by different color shades. The assay protocol involved no sample processing. It 
only required a two-fold dilution, addition of MV
2+
 and tris(2-carboxyethyl) phosphine 
(TCEP), a disulfide reducing agent and 2 min heating at reflux. In this improved method 
a homogenous solution was formed making it easier to distinguish between different 
color shades unlike in the previous method where proteins formed clumps upon heating 
(Figure 2.8).  
 
 
Figure 2.11. Visual detection of Hcy in human serum calibration standards. Left to right: 
Hcy concentrations: 3.79, 6.13, 13.4 and 38.7 μM respectively.66 
 
 
In order to make the assay potentially more user friendly and benign for potential 
application at point of care diagnostics and in home test kits, we continued to improve 
22 
 
upon the design, synthesis and development of room temperature methods for selective 
detection of Hcy. Besides the use of heat to promote the reaction, the MV
2+
 probe is a 
herbicide and so we investigated the use of less- or non-toxic derivatives. We actually 
took a two-pronged approach involving the use of photolytic methods described in 
chapter 3 and the use of novel asymmetric viologen probes described in chapter 4. 
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CHAPTER 3: PHOTOCHEMICAL METHOD FOR SELECTIVE DETECTION 
OF TOTAL HCY IN PLASMA 
 
3.1 Introduction 
The relatively high costs and complexity of the current methods for Hcy detection 
have intensified the need to develop selective, yet simple and inexpensive methods that 
can be used at point of care diagnostics and in home test kits to facilitate the diagnosis 
and treatment of related diseases. Available kits generally use multi-step washing 
procedures and/or specialized storage below -20 ºC, limiting their use, for instance, in 
emerging nations with limited access to refrigeration or electricity. Moreover, even in 
developed countries point-of-care and kit-based assays are of interest considering rising 
health care costs and increasing interest in patient-based monitoring.
83
  
We hypothesized that photolytic methods would afford analogous selectivity via 
the intramolecular HAT mechanism while enabling the assay to be carried out at room 
temperature. Johnson and co-workers reported the photochemical reduction of viologens 
in ethanolic solutions.
84
 A mechanism based on the abstraction of a methylene hydrogen 
atom from EtOH to form a free radical that reduced the viologen in direct sunlight was 
proposed. We envisioned that this approach could be compatible with our HAT 
mechanism for Hcy via photolytic, rather than thermal generation of the Hcy thiyl 
radical. 
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3.2 Results and discussion 
In exploring the use of photolytic methods to detect Hcy, initially we exposed 
solutions of thiols and MV
2+ 
in Tris buffer at neutral pH to direct sunlight at room 
temperature. A blue color was observed within 1 minute in the Hcy sample while other 
thiols solutions remained unchanged (Figure 3.1). 
 
 
 
 
 
 
Figure 3.1 Response of MV
2+
 towards various thiols upon exposure to direct sunlight. Solutions of MV
2+
 
(50 mM) were mixed with thiols (20 µM) in 0.5 M Tris buffer at pH 7, saturated with argon and exposed to 
sunlight. Pictures were taken at 1 min (left) and 2 min (right) after exposure to sunlight. 
 
 To create a laboratory test, we reasoned that an appropriate light source to 
generate the thiyl radical should emit around 325 nm based on the reported S–H bond 
dissociation energy of Cys of 370 kJ mol
-1
.
85
 To this end, we selected a very simple and 
inexpensive compact fluorescent lamp emitting in this region, Reptisun™ consisting of 
10% UVB and 30% UVA. The photolysis experiments were performed using this lamp 
with a light intensity of 6.85 mW cm
-2
 as measured by a Melles Griot Broadband 
Power/Energy Meter 13PEM001. We were able to detect Hcy selectively in human blood 
plasma using MV
2+
 without any interference from Cys and GSH in the range of their 
Blank     
 GSH 
    Cys 
  Hcy 
Blank  GSH 
  Cys 
  Hcy 
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physiological concentrations. Upon irradiation of plasma samples spiked with various 
biothiols, only the Hcy (15 µM) spiked sample showed significant absorption response 
whereas Cys and GSH remained unchanged. The absorption spectra are shown in Figure 
A1, Appendix A. 
 In previous studies, benzyl viologen (BV
2+
), a significantly less toxic chromogen 
than MV
2+
, was found by our group to be more reactive in forming the Hcy α-amino 
carbon-centered radical than MV
2+
 under thermal conditions. BV
2+
 has a less negative 
reduction potential (-370 mV) than MV
2+
 (-446 mV).
86
 Hence we investigated the 
response of BV
2+ 
to Hcy and other thiols using the photochemical method. We observed 
that BV
2+
 indeed displayed selectivity towards Hcy under the new photolytic conditions 
compared to structurally related thiols (Figure 3.2). Moreover, changing the chromogen 
allowed us to lower its concentration from 50 mM (MV
2+
) to 20 mM (BV
2+
). In addition, 
the Hcy response was greater as compared to photolysis in the presence of MV
2+
. An 
irradiation time of just 15 min afforded optimal selectivity and response. 
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Figure 3.2 Spectral response of BV
2+
 towards various spiked thiols in human blood plasma upon 
irradiation. Absorption spectra of solutions of BV
2+
 (20 mM) in human blood plasma and 0.5 M Tris buffer 
(pH 7.0) spiked with 1.5 μM Hcy, 25 μM Cys and 0.6 μM GSH. Plasma (10% v/v) was added to an argon-
saturated solution of viologen, thiol & buffer and irradiated for 15 min using a Reptisun™ lamp. 
 
 Based on the same selectivity pattern and the light source used, the proposed 
mechanism is assumed to be analogous to the thermal reaction for the selective detection 
of Hcy we have previously reported.
74
 It involves the generation of the Hcy thiyl radical 
by photolysis followed by the HAT reaction to form the α-amino carbon centered radical 
that in turn, reduces BV
2+ 
to its corresponding radical cation (BV
•+
) responsible for the 
blue color (Figure 3.3). 
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Figure 3.3 Mechanism for the detection of Hcy involving three steps: (i) photolytic generation of Hcy thiyl 
radical, (ii) hydrogen atom transfer (HAT) turning the thiyl radical into an α-amino carbon-centered radical, 
(iii) reduction of BV
2+
.
83
 
 
Since our ultimate goal was to detect physiological levels of tHcy selectively in 
human blood plasma, the thiols that are bound to the proteins via disulfide bonds had to 
be released by reduction. A selective response of BV
2+
 to Hcy in human plasma was 
observed after using immobilized tris(2-carboxyethyl)phosphine (TCEP gel), 
centrifugation and spiking with various thiols (Figure A2, Appendix A). 
We optimized the sample processing by replacing the centrifugation step with a 
simple filtration of the sample through 0.45 µm PVDF filter vials. The spectral response 
and selectivity was comparable in both methods and excellent selectivity towards tHcy 
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was observed (Figure 3.4). Interestingly, the use of filters improved the overall 
background interference from the plasma components. 
 
 
Figure 3.4 Spectral response of BV
2+
 towards various spiked thiols in reduced human plasma upon 
irradiation. Absorption spectra of solutions of BV
2+
 (20 mM) in reduced human blood plasma and 0.5 M 
Tris buffer (pH 7.0) spiked with 1.5 μM Hcy, 25 μM Cys and 0.6 μM GSH. Plasma was incubated for 1 h 
with TCEP Gel followed by filtration using a Single StEP™ 0.45 μm PVDF filter vial. The reduced, 
filtered plasma (10% v/v) was added to an argon-saturated solution of viologen, thiol and buffer and 
irradiated for 15 min using a Reptisun™ lamp. 
 
The spectral responses of BV
2+
 to Hcy concentration changes, in spiked reduced 
human plasma monitored at 615 nm, increased linearly with increasing Hcy concentration 
over a physiologically relevant concentration range, 0-20 μM with a limit of detection of 
3.35 μM (Figure 3.5). The inset shows the respective spectral data. This linear 
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relationship between absorbance and Hcy concentrations as well as the very low L.O.D 
makes the assay a potential applicant in the quantitation of tHcy.  
Figure 3.5 Spectral response of BV
2+
 towards increasing levels of spiked Hcy in reduced human plasma 
upon irradiation. Absorption spectra of solutions of BV
2+
 (20 mM) in 25% human blood plasma and 0.5 M 
Tris buffer (pH 7.0) spiked with 0–5 µM Hcy. Plasma (25% v/v) was added to an argon-saturated solution 
of viologen, thiol and buffer, and irradiated for 15 min using a Reptisun™ lamp. 
 
To test the limits of possible Cys and GSH interference with the assay, further 
experiments were carried out with added excess amounts of Cys and GSH to reduced 
human plasma solutions. Cys and GSH were found to generate significant response only 
when their concentrations reach 400 µM (almost double the normal concentration in 
healthy individuals) and 100 µM (almost 20 times the normal plasma levels) respectively. 
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At these concentrations, their absorbance response was equivalent to that of 5 µM Hcy 
(Figure. A3, Appendix A). 
To further evaluate the selectivity of the BV
2+
 towards Hcy, control experiments 
using series of other amino acids were performed. Other amino acids produced no 
significant absorption response as compared to Hcy, further demonstrating that BV
2+
 is 
Hcy specific (Figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Spectral response of BV
2+
 towards various spiked amino acids in human plasma upon 
irradiation. Absorption spectra of solutions of BV
2+ 
(20 mM) in human blood plasma and 0.5 M Tris buffer 
(pH 7.0) spiked with 1.5 µM Hcy and 50 µM amino acids (L-Ala, Arg, Gln, Met, Ser, Thr and Phe). 
Plasma (10% v/v) was added to an argon-saturated solution of viologen, amino acids and buffer and 
irradiated for 15 min using a Reptisun™ lamp. 
 
 
 
Hcy 
Plasma & other amino acids 
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3.3 Experimental section 
3.3.1 Materials and instrumentation 
All chemicals were purchased from Sigma-Aldrich and Fisher Scientific and used 
without further purification. The 0.45 μm Single StEP™ PVDF filter vials were 
purchased from Thomson Instrument Company.  UV-visible spectra were acquired on a 
UV-Vis Cary 50 (Agilent Technologies). The light intensity was measured with a Melles 
Griot Broadband Power/Energy Meter 13PEM001.  The light source for the photolysis 
experiments was a ReptiSun™ compact fluorescent lamp (Zoo Med Laboratories Inc.). 
 
3.3.2 Reduction of Human Blood Plasma 
Reconstituted human plasma is incubated with immobilized TCEP gel in a 1:1 
volume ratio at room temperature for 1 h with vortexing. Separation of the reduced 
plasma from the gel can be achieved by centrifugation at 1000 rpm for 5 min or by 
filtration using a Single StEP™ 0.45 μm PVDF filter vial. 
 
3.3.3 General procedure for the photolysis of thiols in the presence of viologens 
In a quartz cuvette sealed with a rubber septum (GL14-S, Starna Cells), a solution 
of viologen (20 or 50 mM in 0.5 M Tris buffer pH 7.0) is deoxygenated by bubbling Ar 
for 5 min. Human plasma (spiked or non-spiked) is added to the cuvette and irradiated for 
15 min with a Reptisun™ lamp. Absorption spectra are collected on a UV-Vis Cary 50. 
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The proportion of the plasma solution is 10% of the total volume after being mixed with 
the viologen solution. 
 
3.4 Conclusion 
We have developed a new, relatively simple and inexpensive photochemical assay 
for the selective detection of total Hcy directly in human blood plasma (Figure 3.7). This 
method has potential practical application in home test kits or point of care diagnostics 
because it involves the use of a less toxic chromogen, an inexpensive commercial light 
source, and simple sample processing, involving only reduction and filtration prior to 
photolysis and UV-Vis monitoring. 
 
 
 
 
 
Figure 3.7 Summary of the photochemical method for detection of tHcy.
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CHAPTER 4: DETECTION OF HCY USING NOVEL ASYMMETRIC 
VIOLOGEN PROBES 
 
4.1 Introduction 
After the success we had with benzyl viologen, we envisioned that viologen 
compounds with higher reduction potentials than benzyl viologen should be more 
reactive and would not require either heat or light to promote the reaction. Additionally, 
in another study conducted by our group in collaboration with Crowe and co-workers, the 
reduction of viologens by α-carbon radicals derived from Hcy and Cys was found to be 
pH dependent.
86
 Symmetric viologens were investigated under reflux conditions and the 
ones with less negative reduction potentials were more reactive towards amino thiols 
(Hcy and Cys) at lower pH (Table 4.1). Moreover, these probes were observed to have a 
faster onset of color formation and more intense color change when the pH was increased 
beyond the endpoint (minimum pH where color formation was observable).  
Based on these findings, we investigated the reaction of phenyl viologen with 
aminothiols at room temperature. No appreciable reaction was observed and so we were 
motivated to design viologen probes with even higher reduction potentials. However, 
there had to be a trade-off between reactivity and selectivity, hence based on the principle 
that diminished reactivity correlates to higher selectivity, we hypothesized that tuning the 
redox properties of viologens by making asymmetric probes bearing electron donating 
and withdrawing groups proximal to the cationic centers would achieve moderate 
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reactivity and allow Hcy to be detected selectively at room temperature without the need 
for heat or light. To this end, five asymmetric viologen probes (Figure 4.1) were 
synthesized, characterized and screened for detection of Hcy in biological samples. 
 
  
 
Entry 
 
Compound 
 
Reduction potential, 
(Volts) 
 
pH endpoint 
of Hcy 
 
 
1 
 
 
 
 
-0.446 
 
5.0 
 
 
2 
 
 
 
 
 
-0.370 
 
 
3.6 
 
 
 
3 
 
 
 
 
 
 
 
 
-0.288 
 
 
 
2.5 
 
 
Table 4.1 Reduction potentials of symmetric viologens and pH endpoint of Hcy 
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Figure 4.1 Structures of novel asymmetric viologen probes 
 
4.2 Results and discussion 
4.2.1 Cyclic voltammetry studies 
To assess potential electronic effects of different substituents on these asymmetric 
viologens, cyclic voltammetry studies were carried out in 80 mM phosphate buffer at pH 
8 using glassy carbon as the working electrode. As expected, all five probes were 
observed to have much less negative reduction potentials compared to methyl viologen 
and behaved as one step redox system (Table 4.2, Figure A5). This implies that these 
probes should be easier to reduce and more likely at room temperature without the need 
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for heat or light.  The trend with increasing reduction potentials (less negative) was found 
to be: PhCV
2+
 (24) < PhNV
2+
 (23) < ACNV
2+
 (26) < NCV
2+
 (25) as expected, due to the 
increase in the strength of the electron withdrawing substituents (nitrile, coumarin and 
ester).  Compound 27 (ACNV
2+
), however, deviated from this trend exhibiting a much 
lesser negative reduction potential than ACNV
2+
 (26) even though the nitrile or cyano is a 
more powerful electron withdrawing group than the coumarin. This could have been due 
to the precipitation we observed in this system and this probe also suffered some 
adsorption. 
At the scan rate of 50 mV/s, viologen probes 26 and 24 voltammograms displayed 
some quasi-reversibility of their reaction systems. This was further confirmed at both 
higher (100 mV/s) and lower scan rates (10 mV/s). The quasi-reversibility may have been 
a result of slow charge transfer processes or the dication may have been further reduced 
to its fully reduced state.
87
 It has also been reported that the formation of spin-paired 
radical cation dimers can cause quasi-reversibility of reduction systems.
88
  
Table 4.2: Reduction potentials of novel asymmetric viologens vs methyl viologen 
Entry Compound Vs NHE (Volts) 
 
1 Methyl viologen (MV
2+
) -0.404 
2 PhCV
2+
 (24) -0.188 
3 PhNV
2+
 (23) -0.161 
4 ACNV
2+ 
(26) -0.133 
5 ACCV
2+ 
(27) -0.123 
6 NCV
2+ 
(25) -0.118 
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4.2.2 Reactivity with amino thiols 
All five probes were screened for their optical sensing behavior towards the amino 
thiols Hcy, Cys and GSH. Screening was done at rt, higher concentrations of thiols (1 
mM), probe (4 mM) and in various buffers at different pH conditions (phosphate pH 6, 7 
and 8; Tris pH 7, 8 and 9; Hepes pH 7 and 8). PhCV
2+
 (25) produced excellent selectivity 
towards GSH and this is described in detail in chapter 5. ACCV
2+
 (27) was selective for 
Hcy at higher concentrations of the thiols (1mM). At pH 8 (phosphate buffer, 80 mM), 
probe 27 developed an intense color upon reaction with Hcy whereas Cys and GSH 
samples had the same color as the blank (Figure 4.2). Attempts to lower the thiol 
concentration below 1 mM resulted in loss of Hcy selectivity and all thiols developed the 
same color as the blank.  
 
Figure 4.2 Response of ACCV
2+
 (27) towards various amino thiols at pH 8. ACCV
2+
 (4 mM) was added to 
thiol solutions (1 mM each) buffered at pH 8 (phosphate buffer (80 mM). From left to right: Blank, Hcy, 
Cys and GSH. The picture was taken 30 min after mixing solutions at room temperature.  
 
UV-Vis absorption spectroscopy was used to monitor the reaction between the 
asymmetric probes and biological thiols. As shown in Figure 4.3, upon mixing solutions 
of NCV
2+
 (25) with amino thiols in phosphate buffer (80 mM) at pH 8, a significant color 
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change was observed in the sample containing Cys after 5 min. However, no significant 
color formation or absorption response was seen in the case of Hcy or GSH samples. 
Over time, Hcy was found to promote a signal. This is in agreement with our earlier study 
under reflux conditions where we found that at higher pH, the colorimetric response of 
symmetric viologen probes towards α-carbon radicals from both Hcy and Cys becomes 
less Hcy selective. 
 
 
Figure 4.3 Spectral response of NCV
2+
 (25) towards various amino thiols at pH 8. Absorption spectra of 
solutions of NCV
2+
 (4 mM) in thiol solutions (1 mM) buffered at pH 8 (phosphate buffer (80 mM). The 
inset shows the picture taken at 10 min. 
 
We investigated the reaction of ACNV
2+
 (26) with Hcy, Cys and GSH in 80 mM 
phosphate buffer (pH 8) and found that Hcy can be detected selectively under these 
conditions without interference from related analytes. Through optimization of the 
reaction, we were able to distinguish Hcy from Cys and GSH at their physiological levels 
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in natural media. Upon adding 26 (350 μM) to solutions of Hcy (15 μM), Cys (250 μM) 
and GSH (6 μM) buffered at pH 8 (phosphate buffer, 80 mM), a marked color change as 
well as an intense absorption response was observed for the Hcy solution.  
While monitoring the change in absorbance at 547 nm as a function of time 
(Figure 4.4) over 2 to 10 min, it was observed that Hcy can be detected selectively 
without any significant interference from both Cys and GSH. Thereafter, Cys reacts in an 
opposing fashion to that of Hcy showing a decreased absorbance peak, far below that of 
both the blank and GSH. The Cys solution peak began to diminish after 10 min, showing 
a plateau at 25 min. Thus, Hcy can be detected selectively without interference from Cys 
and GSH at their physiological levels at 10 min (Figure A4, Appendix A).  
 
 
 
 
 
 
 
 
 
Figure 4.4 Time-dependent spectral response of ACNV
2+
 (26) towards various amino thiols at pH 8. Time-
dependent absorbance changes of 26 (350 μM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) 
buffered at pH 8 (Phosphate buffer, 80 mM). The inset shows the picture taken at 30 min. 
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The absorption spectra displaying opposing reaction behaviors of 26 towards Hcy 
and Cys are shown in Figure 4.5. In the case of Cys the absorbance band at 547 nm 
decreased with concomitant growth of the band at 400 nm over time (Figure 4.5b) 
whereas for Hcy both bands increased with time (Figure 4.5a). This is the first example, 
to our knowledge, of a redox-based probe that detects Hcy and Cys simultaneously at 
typical biological levels found in human plasma. 
(a)                                                                                (b) 
 
 
 
 
 
Figure 4.5 Optical sensing behavior of ACNV
2+
 (26) towards Hcy and Cys at pH 8. (a) Absorption spectra 
of 26 with Hcy (15 μM) over 30 min. (b) Absorption spectra of 26 with Cys (250 μM) over 30 min. 
 
From the screening studies, PhNV
2+
 (23) was found to be the most promising 
probe for detecting Hcy selectively at rt at its physiologically relevant levels. The 
reaction of 23 (2.5 mM) with Hcy (15 μM), Cys (250 μM) and GSH (6 μM) at rt, pH 8 
was investigated by monitoring the changes in absorbance at 550 nm as a function of 
time. Hcy induced a fast response and the absorbance increased rapidly up to about 10 
min and then just gradually thereafter (Figure 4.6). As for Cys and GSH solutions, their 
absorbance changes over 25 min overlapped with the blank demonstrating that this probe 
is Hcy specific.  
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After several hours all the thiols become indistinguishable as the absorbance 
increase due to Hcy, converges with the absorbance levels from GSH and Cys. 
 
Figure 4.6 Time-dependent spectral response of PhNV
2+
 (23) towards various amino thiols at pH 8. Time-
dependent absorbance changes of 23 (2.5 mM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) 
buffered at pH 8 (phosphate buffer, 80 mM).  
 
Based on these findings, we selected 10 min as the optimal reaction time for 
further studies monitoring at 550 nm. The corresponding absorption spectra at 10 min 
showed high selectivity for Hcy, however there was a change via emergence of a peak 
between 400 and 450 nm, showing the blank and Cys increasing relatively slightly 
(Figure 4.7). 
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Figure 4.7 Spectral response of PhNV
2+
 (23) towards various amino thiols at pH 8. Absorption spectra of 
23 (2.5 mM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) buffered at pH 8 (phosphate 
buffer, 80 mM) after 10 min. 
 
Upon lowering the probe concentration to 2 mM, in the presence of thiol solutions 
(15 μM Hcy, 250 μM Cys and 6 μM GSH) buffered at pH 8 (phosphate buffer, 80 mM), 
23 developed a strong pink color and generated a significant absorbance response for Hcy 
without any interference from Cys and GSH (Figure 4.8). Samples containing Cys and 
GSH developed the same color as the blank and their absorption spectra overlapped. 
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Figure 4.8 Spectral response of PhNV
2+
 (23) towards various amino thiols at pH 8. Absorption spectra of 
solutions of PhNV
2+
 (2 mM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) buffered at pH 8 
(phosphate buffer (80 mM). The inset shows the picture taken at 10 min. 
 
The reaction profile of 23 towards amino thiols further confirmed the specificity 
of the probe for Hcy as shown by the rapid increase in absorbance relative to that of Cys, 
GSH and the blank. The absorbance changes for Cys and GSH increased steadily in the 
same manner as the blank and produced no interference to Hcy over the 15 min period 
the reaction was monitored (Figure 4.9).  
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Figure 4.9 Time-dependent spectral response of PhNV
2+
 (23) towards various amino thiols at pH 8. Time-
dependent absorbance changes of 23 (2 mM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) 
buffered at pH 8 (phosphate buffer, 80 mM).  
 
To enable quantitative determination of Hcy, experiments were conducted to 
evaluate the sensing behavior of 23 upon increasing the concentration of Hcy. It can be 
observed in Figure 4.10 that the absorbance changes of 23 versus Hcy concentration 
changes at 550 nm increased linearly proportional to increasing Hcy concentration over a 
physiologically relevant concentration range (0-25 μM) with a very limit of detection of 
2.04 μM. The inset shows the corresponding spectral data. 
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Figure 4.10 Concentration dependent responses of 23 (2 mM) towards Hcy. A Calibration curve for Hcy 
showing a linear relationship between absorbance at 550 nm and Hcy concentration (0-25 μM) at pH 8 
(Phosphate buffer, 80 mM). The inset shows the absorption spectra of probe 23 upon addition of increasing 
Hcy concentrations. 
 
The applicability of 23 in a complex biological system was evaluated using 
commercial human plasma. Upon addition of the probe directly to plasma solutions, a 
very dark pink color developed showing that the probe reacted with proteins. The plasma 
was then deproteinized and, after addition of 23 to plasma samples spiked with various 
amino thiols (15 μM Hcy, 250 μM Cys and 6 μM GSH) at pH 8 (phosphate buffer, 80 
mM), only the Hcy spiked sample displayed significant absorption response whereas Cys 
and GSH spiked solutions responded in the same manner as the blank (Figure 4.11). In 
deproteinized plasma, the probe functioned similarly as in aqueous conditions; however, 
a decrease in the absorbance change was observed as a result of matrix effects. The 
selective response of 23 to Hcy over Cys and GSH in plasma combined with the 
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simplicity of the probe makes it a potential indicator for use in testing Hcy at point of 
care and in a home setting. 
 
Figure 4.11 Spectral response of PhNV
2+
 (23) towards various spiked thiols in deproteinized human plasma 
(dep plasma). Absorption spectra of solutions of PNV
2+
 (2 mM) in human blood plasma (10% v/v) spiked 
with various thiols (15 μM Hcy, 250 μM Cys and 6 μM GSH) buffered at pH 8 (phosphate buffer (80 mM). 
The inset shows the picture taken at 10 min. 
 
4.2.3 Mechanistic studies 
To evaluate whether a free radical mechanism was responsible for Hcy selectivity 
using the asymmetric probes at room temperature or not, Electron paramagnetic 
Resonance (EPR) spectroscopy was performed in the absence and presence of analytes. 
EPR is spectroscopic technique that is used to detect, distinguish and quantify different 
reactive species hence, it plays a pivotal role in the investigations of redox-mediated 
chemical reactions. 
 As expected, the involvement of radicals in probe reactivity was confirmed by 
the EPR spectra (Figure 4.12). However, in the absence of Hcy, the probe itself generated 
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a radical of high amplitude, an indication of a higher concentration of resonating 
paramagnetic species in the sample. The reduction in the probe EPR amplitude in the 
presence of Hcy suggests that Hcy promoted the formation of more radicals which 
consequently formed radical cation dimers. These radical cation dimers are diamagnetic 
hence they do not give an EPR signal. 
89-91
 What was not clear from EPR studies is 
whether the mechanism involves hydrogen atom transfer (HAT) which is more favorable 
for Hcy or some other radical addition process. 
 
Figure 4.12 EPR spectra of PhNV
2+
 (23), (20 mM) in the presence and absence of Hcy (10 mM) at pH 8 
(80 mM, phosphate buffer). 
 
HAT process occurred selectively for Hcy at neutral pH, but at higher pH the 
formation of interfering disulfide radical anions from each thiol renders the method non-
selective. However, at pH 8 using the asymmetric probes, we were able to detect Hcy 
selectively. From our investigations using 2-mercaptoethanol (BME) and 3-
mercaptopropionic acid (MPA), the involvement of HAT cannot be ruled out. BME and 
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MPA are very similar to Hcy in the sense that they possess an –SH group bearing two 
methylene groups but they are not capable of producing the α-amino carbon centered 
stabilized radicals. As shown in Figure 4.13, only the sample containing Hcy turned dark 
red while BME and MPA samples turned yellowish. This suggests that the α-amino 
carbon centered radical is involved in the sensing mechanism. 
 
 
 
 
 
 
Figure 4.13. Response of PhNV
2+
 (23) towards Hcy, MPA and BME. All solutions were composed of 23 (2 
mM), analytes (Hcy, MPA and BME, 100 μM) in 80 mM phosphate buffer, pH 8. Pictures were taken at 30 
min.  
 
4.3 Experimental section 
4.3.1 Materials and instruments 
All chemicals were purchased from Sigma-Aldrich or Acros Organics and used 
without further purification.
1
H-NMR and 
13
C-NMR spectra were recorded on a Bruker 
AMX-400 NMR spectrometer, using TMS as an internal standard. Chemical shifts (δ) are 
given in ppm relative to DMSO-d6 (2.50 ppm, 
1
H, 39.52 
13
C) unless otherwise indicated. 
Blank Hcy BME MPA 
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ESI-HRMS (electrospray ionization - high resolution mass spectrometry) spectra were 
obtained on a Thermo Electron LTQ Orbitrap hybrid mass spectrometer with a dedicated 
Accela HPLC system. Electrochemical measurements were performed with a Gamry 
Reference 600 potentiostat. A three-electrode system was used, consisting of a glassy 
carbon working electrode, a platinum wire counter electrode and a Ag/AgCl reference 
electrode. Reduction potentials were determined using the half wave reduction potential. 
EPR studies were performed using a Bruker (Fremont, CA) EMX spectrometer equipped 
with a high-sensitivity cavity and an Aqua-X sample holder. Spectra were obtained at 
room temperature. UV-visible spectra were collected on a Cary 50 UV-Vis 
spectrophotometer and pH measurements were carried out with an Orion 410A pH meter.  
 
4.3.2 Synthesis of asymmetric viologen probes 
Phenyl-nitrile viologen, PhNV
2+
 (23) 
 
Figure 4.14 Synthesis of phenyl-nitrile viologen, PhNV
2+
 (23)  
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1-(2,4-Dinitrophenyl)-4,4’-bipyridin-1-ium chloride (32)92 
The synthetic procedure was adapted from work by Coe and co-workers but under 
anhydrous conditions.
92
 Under Ar, 4,4’-bipyridine 30 (2 g, 12.81 mmol) is dissolved in 
10 mL of anhydrous EtOH. To this solution is added 2,4-dinitrochlorobenzene 31 (2.59 g, 
12.81 mmol) in 10 mL EtOH dropwise and refluxed for 24 h. The mixture is cooled to rt 
and added to diethyl ether (200 mL) with stirring. The resulting golden-brown precipitate 
is filtered, washed with diethyl ether and dried under vacuum in an argon-saturated glove 
box to give a light brown solid (3.519 g, 85%). 
1
H NMR (400 MHz, DMSO) δ 9.66 (d, J 
= 7.0 Hz, 2H), 9.14 (d, J = 2.5 Hz, 2H), 9.05 – 8.97 (m, 3H), 8.94 (dd, J = 4.5, 1.6 Hz, 
2H), 8.52 (d, J = 8.7 Hz, 1H), 8.23 (dd, J = 4.5, 1.7 Hz, 2H). 
 
1-(Phenyl)-4,4’-bipyridin-1-ium hexafluorophosphate (34)93,94 
Procedures published by Kamogawa et al. and Carballada et al. were modified to 
synthesize compound 34. Compound 32 (1 g, 2.79 mmol) is dissolved in EtOH (20 mL) 
by gentle heating at >60 ºC. A solution of aniline (33) (1.27 mL) in 10 mL EtOH is added 
dropwise and the mixture is stirred at rt for 24 h. The solvent is removed in vacuo and 
diethyl ether (100 mL) added to the residue. This is followed by stirring at rt for 30 min 
and then filtering off the solution. This is repeated two more times until the filtrate is 
clear and the resulting dark-red residue is heated in H2O (50 mL) for 24 h. An aqueous 
solution of 1 M NH4PF6 is added to the filtrate dropwise to give a pale yellow precipitate 
which is filtered, washed with water and dried under vacuum (0.693 g, 66%). 
1
H NMR 
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(400 MHz, DMSO) δ 9.53 – 9.49 (m, 2H), 8.92 (d, J = 6.0 Hz, 2H), 8.81 – 8.77 (m, 2H), 
8.15 (dd, J = 4.5, 1.7 Hz, 2H), 7.96 – 7.91 (m, 2H), 7.80 – 7.76 (m, 3H). 
 
Phenyl-nitrile viologen, PhNV
2+
 (23) 
Under argon, compound 36 (0.200 g, 0.529 mmol) and bromoacetonitrile (0.368 
mL, 5.29 mmol) are dissolved in 20 mL of anhydrous acetonitrile (MeCN). The mixture 
is heated to reflux for 24 h and cooled to rt. The resulting precipitate is filtered, washed 
with fresh MeCN, and dried under vacuum to yield a yellow powder (0.0985 g, 43%). 
1
H 
NMR (400 MHz, DMSO): δ 9.69 (d, J = 7.0 Hz, 2H), 9.50 (d, J = 7.0 Hz, 2H), 8.95 (dd, J 
= 9.9, 7.0 Hz, 4H), 7.98 – 7.94 (m, 2H), 7.82 – 7.79 (m, 3H), 6.05 (s, 2H). 13C NMR (101 
MHz, DMSO) δ 150.06, 149.02, 146.59, 145.96, 142.23 131.63, 130.26, 127.18, 126.66, 
124.81, 114.14 47.80.  HR ESI [M - H]
 +
, m/z: 272.1188; calc for C18H14N3
2+
; 272.1187, 
[M – C2H2N]
 +
, m/z: 233.1079 calc for C16H13N2
+ 
233.1077. 
 
Phenyl-coumarin viologen, PhCV
2+
 (24) 
 
 
Figure 4.15 Synthesis of phenyl-coumarin viologen, PhCV
2+
 (24)  
 
Under argon, compound 34 (0.200 g, 0.529 mmol) and 3-(bromoacetyl) coumarin 
35 (0.706 g, 2.64 mmol) are dissolved in 20 mL of anhydrous MeCN. The mixture is 
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heated to reflux for 24 h and cooled to rt. The resulting precipitate is filtered, washed 
with fresh MeCN, acetone and dried under vacuum to yield a yellow powder (0.187 g, 
61%). 
1
H NMR (400 MHz, DMSO): δ 9.74 (d, J = 6.5 Hz, 2H), 9.32 (d, J = 6.4 Hz, 2H), 
9.04-9.00 (m, 5H), 8.13 (d, J = 7.0 Hz, 1H), 8.00 (d, J = 3.7 Hz, 2H), 7.89 (t, J = 7.8 Hz, 
1H), 7.83 – 7.78 (m, 3H), 7.61 (d, J = 8.4 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 6.48 (s, 2H). 
13
C NMR (101 MHz, DMSO) δ 187.59, 158.79, 154.89, 149.60, 147.23, 145.94, 142.15, 
135.98, 131.54, 130.25, 126.53, 125.57, 124.93, 121.12, 117.98, 116.47, 68.95.  HR ESI 
[M-H]
 +
, m/z: 419.1396; calc for C27H19N2O3
2+
419.1374, [M+OH]
 + 
m/z: 437.1457 calc 
for C27H20N2O4
2+
437.1478, [M – C11H7O3]
 +
, m/z: 233.1079 calc for C16H13N2
+ 
233.1066, 
[M+2H]
2+ 
m/z: 420.1474 calc for C27H20N2O3
2+
210.0726.  
 
Nitrile-Coumarin viologen, NCV
2+
 (25) 
 
Figure 4.16 Synthesis of Nitrile-coumarin viologen, NCV
2+
 (25). 
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1-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)-[4,4'-bipyridin]-1-ium bromide (36) 
Compound 36 is synthesized following a procedure reported by our group.
95
 4,4’-
bipyridine 30, (1.46 g, 9.36 mmol) and 3-(bromoacetyl)coumarin 37 (1 g, 3.74 mmol) are 
dissolved in 40 mL of acetone and stirred at rt for 3 h.  The precipitate is filtered, washed 
with acetone and dried under vacuum to give a purple precipitate (1.279 g, 81%).  
1
H 
NMR (400 MHz, DMSO): δ 9.13 (d, J = 6.9 Hz, 2H), 9.02 (s, 1H), 8.91 (dd, J = 4.5, 1.6 
Hz, 2H), 8.77 (d, J = 7.0 Hz, 2H), 8.15 – 8.08 (m, 2H), 7.92 – 7.84 (m, 1H), 7.61 (d, J = 
8.4 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 6.39 (s, 2H). 
 
Nitrile-coumarin viologen, NCV
2+
 (25) 
The hexafluorophosphate salt (37) was prepared by dissolving the bromide salt 
(36) in water (15 mL) followed by dropwise addition of an aqueous solution of 1 M 
NH4PF6 until a solid precipitated completely. The light purple precipitate is filtered, 
washed with H2O and dried under vacuum. Under argon atmosphere, compound 33 
(0.200 g, 0.410 mmol) and bromoacetonitrile (0.286 mL, 4.10 mmol) are dissolved in 20 
mL of anhydrous acetonitrile (MeCN). The mixture is heated to reflux for 5 h and cooled 
to rt. The resulting yellow precipitate is filtered, washed with fresh MeCN, recrystallized 
from EtOH and dried under vacuum to yield a yellow powder (0.125 g, 56%). 
1
H NMR 
(400 MHz, DMSO): δ 9.53 (d, J = 7.0 Hz, 2H), 9.26 (d, J = 7.0 Hz, 2H), 9.01 (s, 1H), 
8.90 (t, J = 7.0 Hz, 4H), 8.12 (dd, J = 7.9, 1.5 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.61 (d, J = 
8.4 Hz, 1H), 7.52 (dd, J = 11.7, 4.3 Hz, 1H), 6.43 (s, 2H), 6.10 (s, 2H). 
13
C NMR (101 
MHz, DMSO) δ 187.83, 158.67, 154.90, 150.43, 149.73, 147.30, 146.50, 136.02, 131.59, 
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127.16, 126.48, 125.56, 121.10, 117.94, 116.40, 114.10, 69.09, 47.76.  HR ESI [M-H]
+
 
m/z: 382.1181 calc for C23H16N3O3
2+
 382.1175. 
 
Acetyl-nitrile viologen, ACNV
2+
 (26) 
Compound 26 was synthesized using microwave irradiation by modifying the 
method used by Lambert and co-workers to synthesize asymmetric viologens.
96
 
 
 
Figure 4.17 Synthesis of Acetyl-nitrile viologen, ACNV
2+
 (26)  
 
1-(acetoxymethyl)-[4,4'-bipyridin]-1-ium bromide (41) 
4,4’-bipyridine 30, (0.500 g, 3.20 mmol) and bromomethylacetate (0.157 mL, 
1.60 mmol) are dissolved in 4.00 mL of anhydrous DCM in a sealed microwave vial 
equipped with a stir bar. The mixture is irradiated on a Biotage Initiator at 60 
º
C for 1 h. 
The vial is cooled to rt and the resulting precipitate is filtered, washed with fresh DCM 
and dried under vacuum overnight to give a very pale yellow solid (0.653 g, 66 %). 
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1
H NMR (400 MHz, DMSO): δ 9.34 (d, J = 7.0 Hz, 2H), 8.89 (d, J = 6.0 Hz, 2H), 8.69 
(d, J = 7.0 Hz, 2H), 8.05 (dd, J = 4.5, 1.7 Hz, 2H), 6.45 (s, 2H), 2.17 (s, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 169.72, 154.57, 151.03, 145.67, 140.67, 125.32, 122.03, 78.85, 
20.57.  HR ESI [M-H]
+
, m/z: 229.0977; calc for  C13H13N2O2
+
 229.0969. 
 
Acetyl-nitrile viologen, ACNV
2+
 (26) 
The hexafluorophosphate salt (40) was prepared following the procedure used for 
compound 37 above. Compound 40 (0.100 g, 0.268 mmol) and bromoacetonitrile (0.186 
mL, 2.68 mmol) are dissolved in 4.00 mL of anhydrous MeCN in a sealed microwave 
vial equipped with a stir bar. The mixture is irradiated on a Biotage Initiator at 100
0
C for 
30 min. The vial is cooled to rt and the resulting precipitate filtered, washed with fresh 
DCM and dried under vacuum overnight to give a green-yellowish solid (0.047 g, 41 %). 
1
H NMR (400 MHz, DMSO): δ 9.57 – 9.46 (m, 4H), 8.86 (dd, J = 14.3, 6.6 Hz, 4H), 6.51 
(s, 2H), 6.09 (s, 2H), 2.18 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 169.48, 150.32, 
146.31, 127.01, 114.03, 79.31, 47.71, 20.56.  HR ESI [M-H]
+
, m/z: 268.1086 calc for 
C15H14N3O2
2+
 268.1077, [M – C2H2N]
 +
, m/z: 229.0977; calc for  C13H13N2O2
+
 229.0969, 
[M + CH3]
 +
, m/z: 283.1321 calc for 283.1128 
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Acetyl-Coumarin viologen, ACCV
2+
 (27) 
 
  
Figure 4.18 Synthesis of Acetyl-coumarin viologen, ACCV
2+
 (27). 
 
Under Ar, 3-(bromoacetyl) coumarin 35 (0.358 g, 1.34 mmol) was dissolved in 15 
mL of anhydrous MeCN and heated to reflux. A solution of compound 40 (0.100 g, 0.268 
mmol) in 10 mL anhydrous MeCN is added dropwise and the mixture is refluxed for 5 h. 
After cooling to rt, the resulting precipitate is filtered, washed with fresh MeCN and dried 
under vacuum to yield an orange powder (0.0618 g, 39%). 
1
H NMR (400 MHz, DMSO): 
δ 9.55 (d, J = 6.9 Hz, 2H), 9.29 (d, J = 6.9 Hz, 2H), 9.02 (s, 1H), 8.92 (t, J = 7.0 Hz, 4H), 
8.12 (dd, J = 7.8, 1.4 Hz, 1H), 7.92 – 7.85 (m, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.52 (dd, J = 
11.6, 4.2 Hz, 1H), 6.54 (s, 2H), 6.46 (s, 2H), 2.19 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 
187.74, 169.56, 158.74, 154.72, 150.99, 149.81, 149.08, 147.20, 146.03, 136.14, 131.67, 
126.72, 125.56, 121.09, 117.76, 116.35, 79.18, 69.05, 20.52.  HR ESI [M-H]
+
, m/z: 
415.1294 calc for C24H19N2O5
2+
 415.1279, [M+OH]
+
, m/z: 433.1389 calc for 
C24H21N2O6
2+
 433.1384, [M-C3H6O2]
+
, m/z: 343.1077; calc for  C21H15N2O3
+
 341.1073, 
[M-C10H6O3]
+
, m/z: 243.1134; calc for  C14H15N2O2
+
 243.1124. 
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4.3.3. Cyclic voltammetry  
Glassy carbon working electrodes were polished with 0.05 µm alumina Struers 
OP-Alumina suspension on a Buehler microcloth, followed by sonication in deionized 
H2O. All electrochemical cyclic voltammograms used a Pt flag counter electrode (1 cm
2
) 
and a Ag/AgCl reference electrode. The electrode was immersed in an aqueous solution a 
viologen (4 mM) buffered at pH 8 and cycled at a rate of 10, 50 or 100 mV/s. All 
experiments were performed at ambient temperature.  
 
4.3.4 General procedure for the UV/Vis absorption responses of asymmetric viologen 
probes towards thiols. 
 The probe was added to solutions of thiols in buffer at pH 8.0 (phosphate buffer, 
80 mM) and vortexed for about 5 seconds to ensure thorough mixing. The solution was 
then pipetted into a cuvette for UV-Vis spectra collection. In the case of deproteinized 
plasma, its proportion was 10% of the total volume after being mixed with buffer and 
probe solutions. Deproteinized plasma was obtained by reconstituting lyophilized 
commercial human plasma with Milli-Q® grade water to 1/3 of the reconstitution 
volume. Proteins were then precipitated using MeCN (two thirds of the reconstitution 
volume) followed by centrifugation at 4,000 rpm for 30 min. The supernatant liquid was 
decanted, lyophilized for 12 h and stored at 4 ºC for further use.  
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4.4 Conclusion 
We have developed novel redox-based asymmetric viologen probes that can 
selectively detect Hcy, Cys and GSH without any interference from each other. PhNV
2+
 
(23) and ACNV
2+
 (26) have been proved to be sensitive probes that can detect Hcy 
selectively at relevant plasma concentrations, which are significantly lower compared to 
the concentration of competing analytes such as Cys.  Additionally, a linear calibration 
curve obtained for 23 with increasing Hcy concentration over a physiologically relevant 
range (0-25 μM) with a very low L.O.D of 2.04 μM demonstrating a high potential for 
quantitation of total Hcy in complex biological samples.  
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CHAPTER 5: SELECTIVE DETECTION OF GSH USING OPTICAL PROBES 
 
5.1 Significance of glutathione to public health 
GSH plays a significant role in the detoxification of free radicals and reactive oxygen 
species (ROS) thus maintaining and regulating the redox status of cells.
97,98
 Diminished 
levels of GSH which manifest largely through an increased susceptibility to oxidative 
stress are characteristic of chronic diseases. Chronic diseases are characterized by long 
duration and relatively slow progression and include heart disease, stroke, cancer, chronic 
respiratory diseases and diabetes.  They are the leading cause of mortality in the world, 
accounting for approximately 63% of all deaths.
99
 
Results published in 1999 by Beutler E. et al., revealed a decrease in erythrocyte 
GSH content in patients affected by γ-glutamylcysteine synthetase deficiency and 
hemolytic anemia.
100
 Recently, Atkuri and co-workers reported intracellular reduced 
glutathione (GSH) deficiency in mitochondrial disorders and organic acidemias.
101
  
Mitochondrial disorders can cause organ failure, seizures, stroke-like episodes and 
premature death. Depleted intracellular GSH levels were also reported in various 
neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.102,103 
Oxidative stress is the major proposed pathogenic mechanism for neurodegenerative 
disorders in which mitochondrial defects have been reported. GSH monitoring is a 
promising new means to diagnose mitochondrial disorders and in clinical trials to monitor 
autism by indexing the imbalance of oxidative and anti-oxidative stress systems in 
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autistic patients.
101
 Mancuso et al. reinforced the same findings that oxidative stress 
biomarkers which include GSH may be useful in the detection of redox imbalance in 
mitochondrial diseases and provision of non-invasive tools for monitoring disease 
status.
104
  Whole blood GSH measurements have also been used to monitor the responses 
of patients to glutamine (GLN) therapy following open heart surgery.
105
  
Conversely, elevated GSH levels generally increase antioxidant capacity and 
resistance to oxidative stress, and this is observed in many types of cancer cells.
98
 Higher 
levels of GSH have been reported in a number of different human cancer tissues 
including, bone marrow, breast, colon and lungs.
106-108
 While GSH is important in the 
detoxification of carcinogens, its elevated state in cancerous cells and solid tumors makes 
them more resistant to chemo- and radiotherapy.
109
  
 
5.2 Current methods for GSH detection 
Current diagnostic methods require a separation step (chromatographic
110
), fragile 
materials (that need skilled handling and specialized storage) and intensive sample 
processing.
111,112
  Various useful innovative indicators and probes for GSH detection 
have been recently reported. However, many of them have no specificity for GSH over 
other structurally similar, competing thiols.
113-116
 Many reports for instance, claim GSH 
selectivity via fluorescent indicators, however, close scrutiny often reveals that the stated 
selectivity suffices only in specific applications such as cell imaging, and that Cys, Hcy 
and other sulfhydril-containing species interfere with the purported GSH indicators.
113-116
  
61 
 
 Lim et al., reported an activated coumarin-3-phenyl enone fluorescent probe, 41 
which responded selectively and ratiometrically to GSH and Cys over other natural 
amino acids through the Michael addition reaction.
114
 However, their results showed a 
significant response from Cys although the GSH response was greater. Additionaly, Hcy 
another structurally related analyte which could potentially interfere with the system was 
not investigated using this probe. Since the mechanism involves a Michael addition 
reaction of the probe to the thiol group, this probe will react with all thiols making it non-
specific for GSH only. Higher concentrations of GSH of 20 mM were used which do not 
reflect the physiological levels in both plasma and blood cells. 
 
Figure 5.1.  Michael addition reaction of 41 with thiols.
114
 
 
Another non-specific thiol probe, 1,3,5,7-tetramethyl-8-phenyl-(2-maleimide)-
difluoroboradiaza-s-indacene, (TMPAB-o-M) was shown to respond to N-acetylcysteine 
and used for labeling BSA in SDS-PAGE.
117
  Subsequently, the same probe was applied 
in the selective spectrofluorometric determination of glutathione in clinical and biological 
samples.
118
 Due to the probe’s lack of specificity, complex sample preparation and a 
separation step were needed to help detect GSH selectively. 
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There are very few indicators that achieve good selectivity for GSH over other 
biological thiols. However, some of them have only been applied in cells where GSH 
concentrations are higher (1-2 mM) but have not been applied in plasma where where its 
concentrations are very low (1-6 μM) compared to those of Cys (135–300 μM) and Hcy 
(5–15 μM). 6,7,10,16 Examples include a monochlorinated BODIPY-based ratiometric 
fluorescent sensor developed by Niu and co-workers,
116
 a bis-spiropyran ligand 
developed for cellular imaging,
119
 a quantum-dot-based off-on fluorescent probe
120
 and 
cyanine-based fluorescent probes recently reported by Yin et al.
121
 Our group also 
reported a dual emission fluorescent probe, a rhodol thioester that detects GSH and 
Cys/Hcy simultaneously.
122
 
We had an impressive achievement in developing a simple probe that can detect 
GSH levels both in plasma and in cells. This highly sensitive and selective probe is 
acrylate-based where the discrimination of GSH from structurally related analytes is 
catalyzed by a cationic surfactant, cetyltrimethylammonium bromide (CTAB) micelle. 
The resorufin-acrylate indicator was successfully applied in deproteinized human blood 
plasma and will be described in detail in section 5.3.
123,124
 Prior to that, Strongin’s group 
had designed a seminaphthofluorescein (SNF) acrylate-based probe (43) which detected 
Cys selectively over GSH and Hcy.
125
 The sensing mechanism was based on a tandem 
conjugate addition of 43 to the thiol group followed by an intramolecular cyclization 
reaction to release the free SNF fluorescent dye (Figure 5.2). The conjugate addition 
reaction to form thio-ethers is non-selective; however, the second step (intramolecular 
cyclization) differs among the three thiols due to different kinetics. The intramolecular 
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cyclization reaction to form a 7-membered ring for Cys is kinetically favored over the 
formation of 8- and 12-membered rings in the case of Hcy and GSH respectively. Thus 
Cys selectivity was based on different relative rates of intramolecular cyclization. 
 
Figure 5.2 Proposed mechanism for discrimination of Cys from Hcy using probe 45.
125
 
 
To achieve selective detection of GSH over Cys and Hcy, one would need to 
overcome the formidable challenge of favoring the formation of a larger ring (12-
membered for GSH) over a 7- and 8-membered ring in the case of Cys and Hcy 
respectively. Wei and co-workers reported that cetyl-trimethyl-ammonium bromide 
(CTAB, 46) micelles can catalyze the intramolecular ring closure of larger rings, 
reversing the expected kinetics based on ring size.
126
 In their study, they measured the 
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rates of cyclization of an intramolecular Williamson ether reaction (Figure 5.3) for the 
formation of 7- to 20-membered rings and observed a 500-1500-fold decrease in ring 
closure on going from a 7-membered ring to a 14-membered ring in homogeneous 
environments (99% DMSO, 75% EtOH) and only a 6-fold decrease in the micelle-
localized reaction.  
 
 
Figure 5.3 Intramolecular Williamson ether reaction.
126
 
In another study, it was reported that GSH binds the positively charged surface of 
CTAB micelle through some electrostatic interactions between the carboxylate groups 
and the cationic CTAB surface.
127
 Based on this, we envisioned that a relatively smaller, 
flat and more planar dye similar to PhSeO2H (Figure 5.4) should fit well within the 
micelle allowing a good self-assembly of CTAB micelle with the probe through 
hydrophobic and electrostatic interactions in water bringing it in close proximity to GSH. 
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We then proceeded to design a very simple resorufin-acrylate based probe that 
successfully detected GSH in human plasma. 
 
Figure 5.4 Proposed Model for Selenium-Mediated Micellar.
127
 
*Adapted with permission from Langmuir, 2007, Volume 23, pages 1518-1522; Huang, X.; Dong, Z.; Liu, 
J.; Mao, S.; Xu, J.; Luo, G.; Shen, J. Selenium-Mediated Micellar Catalyst: An efficient Enzyme Model for 
Glutathione Peroxidase-like Catalysis. Copyright 2007 American Chemical Society. 
 
To rule out the possibility of detecting GSH using acrylate-based probes which 
are large and 3-dimensional in shape in micelles, we designed a near-infrared (NIR) 
naphthofluorescein-based dye (49) and investigated its reaction selectivity in the presence 
of aminothiols. This probe was selective for Cys, thus eliminating any possibilities of 
achieving GSH selectivity with non-planar compounds. As predicted, the resorufin – 
acrylate probe (50) was successful in detecting GSH in deproteinized human plasma 
without any interference from related analytes such as Hcy and Cys. While developing 
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asymmetric viologen probes specific for Hcy, to our surprise one of them, PhCV
2+
 (24), 
detected GSH selectively without any interference from Hcy and Cys. This will be 
described in the next section. 
 
Figure 5.5 Structures of acrylate-based probes 
 
5.3 Results and discussion 
5.3.1 Acrylate-based probes 
Probe 49 showed excellent selectivity towards Cys due to the reported kinetically 
favored formation of a 7-membered ring in the intramolecular cyclization step over the 8- 
and 12-membered rings for Hcy and GSH respectively. Upon reacting 49 with amino 
thiols, only the Cys containing sample developed a green color of the free dye whereas 
Hcy and GSH remained unchanged (Figure 5.6). Additionally, a significant absorbance 
response was observed for Cys and absolutely no response for related analytes. The 
concentrations of Cys and GSH used reflect their normal biological concentration in 
human plasma whereas the 15 µM of Hcy was used to represent mild homocysteinemia. 
These findings indicate that this probe can serve as a selective “off-to-on” dosimeter for 
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Cys with potential application in natural media. Moreover, the results confirmed our 
hypothesis that a relatively smaller, flat and more planar dye and not a large, 3 
dimensional dye would fit well within the micelle allowing a good self-assembly of 
CTAB micelle with the probe for reaction with GSH.  
 
Figure 5.6 CTAB-mediated response of 49 towards various aminothiols at pH 7.4. Absorption spectra of 
solutions of 49 (50 μM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) buffered at pH 7.4 
(Phosphate buffer (50 mM). The inset shows the picture taken at 10 min. 
 
To this end a resorufin acrylate probe (50) was developed and successfully 
applied in detecting GSH selectively via my coworkers using a CTAB micelle.
123
 
Solutions of GSH, Cys and Hcy (2 equiv) with 50 in pH 7.4 phosphate buffer generated a 
characteristic strong pink color immediately upon addition of CTAB only in the presence 
of GSH (Figure 5.7a). Other amino acids, such as Hcy and Cys, did not exhibit 
significant changes under the same conditions. This interesting feature indicates that 4-
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CTAB system can serve as a selective visual inspection dosimeter for GSH. 
Corresponding fluorescence increases were also observed (Figure 5.7b). Fluorescence 
upon reaction with GSH reached a plateau in less than 2 min. 
 
Figure 5.7 Surfactant-mediated responses of solutions containing 50-CTAB towards various thiols at pH 
7.4. (a) Absorption spectra of 50 (2.5 μM) upon addition of thiols (2 equiv) in 2.0 mM CTAB media 
buffered at pH 7.4 (phosphate buffer, 50 mM). The inset shows color changes of the solution of 4 (10 μM) 
upon addition of thiols (2 equiv) in 2.0 mM CTAB media buffered at pH 7.4 (phosphate buffer, 50 mM). 
The picture was taken immediately upon addition of CTAB; (b) Fluorescence spectra (λex = 565 nm) of 50 
(2.5 μM) upon addition of thiols (2 equiv) in 2.0 mM CTAB media buffered at pH 7.4 (phosphate buffer, 
50 mM). Spectra were taken immediately upon addition of CTAB. The inset shows time-dependent 
fluorescence changes (λem = 587 nm) of the same system. 
 
Based on the above results, we proposed a plausible mechanism for the GSH 
selectivity of the probe-CTAB system that involves the conjugate addition of GSH to 50 
to generate 51, which in turn undergoes an intramolecular cyclization/elimination 
reaction sequence catalyzed by the CTAB micelle releasing the free resorufin dye (Figure 
5.8), resulting in the recovery of the fluorescence. Formation of the 12-membered ring 
(52) and the free resorufin dye (53) were confirmed by HRMS. 
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Figure 5.8. Proposed mechanism for the selective detection of GSH in CTAB medium that involves a 
conjugate addition reaction followed by a micelle-promoted 12-membered ring formation/elimination 
sequence. 123 
 
5.3.2 Improved resorufin-acrylate selectivity towards GSH
124
 
While the probe-CTAB-GSH signal is high at pH 7.4, it is known that acrylate 
esters are susceptible to hydrolysis at high pH and that GSH is also relatively unstable 
under the same conditions (half-life of 9 hours at pH 7.4 compared to 16 hours at pH 
6.5).
128
 Chemical stability of fluorogenic probes is very important because spontaneous 
hydrolysis raises background fluorescence and compromises the ability to assess its 
reactivity with analytes. To address the challenge of probe hydrolysis, my own work 
involved investigating and optimizing the effect of pH on the chemical stability of the 
probe. 
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The spectral behavior of the probe-CTAB system was examined over a wide 
range of pH values (pH 5.5 to pH 8) and its response to the various thiols was studied at 
lower pH values. As expected, the acrylate-based probe 50 showed the greatest 
background signal at the higher pH values investigated. The probe-CTAB system was 
most stable at lower pH values (Figure 5.9). 
 
Figure 5.9 Spectral behavior of the probe-CTAB system under different pH conditions (50 mM phosphate 
buffer). Time-dependent absorbance changes of a solution of 50 (2.5 µM) at 580 nm in CTAB media (2 
mM) buffered at pH 5.5 to 8. 
 
We investigated the response of 50 towards amino thiols at pH 6 and observed 
that the reaction is less rapid as compared to pH 7.4 (Figure 5.10) and the selectivity 
towards GSH was further enhanced through the complete elimination of any residual Cys 
and Hcy response (Figure 5.11). Very little background interference from the hydrolysis 
of the probe is observed starting at 10 min after mixing. Thus, pH 6 was chosen for 
further application studies in plasma. 
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Figure 5.10 Surfactant mediated response of the probe-CTAB system towards various thiols (5 μM)  at pH 
6.0. Time-dependent absorbance changes of a solution of 50 (2.5 µM) at 583 nm in CTAB media (2 mM) 
buffered at pH 6 (phosphate buffer, 50 mM). 
 
Figure 5.11 Absorption spectra of 50 (2.5 μM) upon addition of thiols (2 equiv) in 2.0 mM CTAB media 
buffered at pH 6 (phosphate buffer, 50 mM) at 8 min.  
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 To evaluate the applicability of the probe-CTAB system in complex natural 
media, fluorescence determination was performed in 10% deproteinized human plasma. 
Plasma proteins were precipitated using MeCN (two thirds of the reconstitution volume) 
and removed by centrifugation at 4,000 rpm for 30 min. The supernatant liquid was 
diluted and added to a solution of 50 (1 μM) in phosphate buffer (pH 6, 50 mM) in the 
presence of 2.0 mM CTAB. The fluorescence response of replicate (n = 3) samples and 
GSH spiked samples were monitored as above and the GSH content in the plasma sample 
was determined from the regression equation of a standard calibration curve (Figure 5.12 
(a) and (b)). The GSH content of the plasma sample was determined to be 3.24 ± 0.14 
μM, which is well within the reported GSH concentration range for human plasma 
samples from healthy individuals. 
129
  
 
Figure 5.12. Determination of GSH in human plasma using the probe-CTAB system. (a) Calibration curve 
of 50 (1.0 μM) in 2.0 mM CTAB media buffered at pH 6 (phosphate buffer, 50 mM) showing a linear 
relationship between fluorescence intensity (λex = 565 nm, λem = 587 nm) and GSH concentration (0.1–
1.2 μM); (b) Fluorescence spectra (λex = 565 nm) of 50 (1.0 μM) upon addition of GSH (0–1.0 μM) to 
10% deproteinized plasma diluted with 2.0 mM CTAB media buffered at pH 6.0 (phosphate buffer, 50 
mM). The calibration curve and emission spectra were collected 8 min after mixing. 
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 Accuracy assessment of the method was conducted using recovery 
experiments.
130
 Recoveries of the known spiked amounts of GSH were between 99.2% 
and 102.3% with a generally satisfactory precision (Table 5.1). These results revealed the 
potential applicability and reliability of using 50 in quantitative detection of GSH in 
human plasma.  
Table 5.1. Determination of GSH content in 10% deproteinized human plasma samples. 
Sample GSH Spiked 
(µM) 
GSH Measured 
 (µM) 
Recovery 
(%) 
RSD 
(%) 
10% Plasma 0 0.324 - 4.42 
10% Plasma + GSH 0.3 0.631 102.3 4.90 
10% Plasma + GSH 0.6 0.919 99.2 4.24 
10% Plasma + GSH 0.9 1.224 100.0 5.88 
 
5.3.3 Asymmetric viologen-based probe 
The response of PhCV
2+
 (24) towards various aminothiols was examined at pH 9 
(Tris buffer, 0.5 M). Initial investigation of 24 at a concentration of 1 mM in thiols 
solutions (1 mM) showed no selectivity. The reaction was optimized by lowering 
probe/thiols concentration and surprisingly at 500 μM probe concentration and 500 μM, a 
useful absorption response was observed in the presence of GSH (Figure A8, Appendix 
A). A minimal response was promoted by the presence of Hcy and Cys. Further 
optimization via lowering the thiol concentration to 250 μM resulted in the complete 
elimination of residual responses from Hcy and Cys, thereby affording excellent GSH 
selectivity (Figure 5.13). Attempts to lower thiol concentration to physiological levels (15 
μM Hcy, 250 μM Cys and 6 μM GSH) led to loss of selectivity. Hence, this probe cannot 
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be applied to determine GSH at relevant plasma levels. However, the probe is potentially 
of high utility for detecting GSH in blood where levels are higher (1-2 mM). 
1,4
  
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Spectral response of PhCV
2+
 (24) towards various amino thiols at pH 9. Absorption spectra of 
solutions of PhCV
2+
 (500 μM) in thiol solutions (250 μM) buffered at pH 9 (Tris buffer (200 mM). The 
inset shows the picture taken at 25 min. 
 
Concentration-dependent studies were performed, and absorbance changes at 510 
nm were found to be linearly proportional to the concentrations of GSH (0–500 μM). 
This suggested a potential application towards quantitative determination of GSH (Figure 
5.14).  
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Figure 5.14. Absorption spectral changes of 24 upon addition of increasing concentrations of GSH (0-500 
μM). Inset: absorbance changes at 510 nm as a function of the concentrations of GSH. All solutions were 
composed of 200 mM Tris buffer (pH 9) and 24 (500 μM). 
 
To investigate the possible involvement of free radicals, EPR studies of the probe 
were carried out in the absence and presence of GSH. Interestingly, 24 alone produced an 
EPR signal of greater amplitude compared to the one generated in the presence of GSH 
(Figure 5.15).  Thus, the presence of GSH diminished the amount of radical species that 
were generated by the probe itself. Although this experiment suggested the possibility of 
a free radical mechanism being involved, after samples were taken out from the EPR 
instrument, we observed precipitation, an indication that the data may not reflect the 
mechanism. Further investigations were performed including mass spectrometry. NMR 
studies were not possible because of solubility issues of the probe at higher 
concentrations needed. 
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Figure 5.15 EPR spectrum of PhCV
2+
 (24), (20 mM) in the presence and absence of GSH (10 mM) at pH 9 
(200 mM, Phosphate buffer). 
 
Since Hcy selectivity would be more favorable if all thiols are forming the 
reducing, α-amino carbon-centered radical, we propose that there are other factors 
enabling selectivity for GSH. These include favorable structural and/or electrostatic 
interactions between the probe (cationic) and anionic GSH. These also could promote  
supramolecular assembly formation.
131
 
Molecular calculations (MM2, Gasteiger-Hückel charges) using the SYBYL-X™ 
(version 2.0, Certara, L.P.) suite reveal that the interactions of 24 with GSH are in fact, 
driven by electrostatics and the spatial configuration of 24 is dramatically modified as a 
result (Figure 5.16).  
-2.E+06
-2.E+06
-1.E+06
-5.E+05
0.E+00
5.E+05
1.E+06
2.E+06
2.E+06
3430 3450 3470 3490 3510 3530
E
P
R
 s
ig
n
al
 i
n
te
n
si
ty
 
Magnetic Field [G] 
24
GSH
24 + GSH
77 
 
 
Figure 5.16. Energy minimized structures of 24 (left) and 24 in the presence of GSH (right). 
 
 5.4 Experimental section 
5.4.1 Materials and instruments 
All chemicals were purchased from Sigma-Aldrich or Acros and used without 
further purification.
1
H-NMR and 
13
C-NMR spectra were recorded on a Bruker AMX-400 
NMR spectrometer, using TMS as an internal standard. ESI-HRMS (high resolution mass 
spectrometry) spectra were obtained on a Thermo Electron LTQ Orbitrap hybrid mass 
spectrometer. UV-visible spectra were collected on a Cary 50 UV-Vis 
spectrophotometer; Fluorescence spectra were collected on a Cary Eclipse (Varian, Inc.) 
fluorescence spectrophotometer with slit widths set at 5 nm for both excitation and 
emission, respectively. The high voltage of the fluorescence spectrophotometer was set at 
550 V and pH measurements were carried out with an Orion 410A pH meter. 
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5.4.2 Synthesis of the NIR acrylate 49 
 
Figure 5.17 Synthesis of NIR acrylate probe 51 
 
Improved synthesis of 1, 13-dihydroxy-3' H-spiro[dibenzo[c,h]xanthene-7,1'-
isobenzofuran]-3'-one, 56 
 
This compound was previously synthesized by our group 
132
 in 18% yield and 
here we modified the procedure by allowing the reaction to run for a longer time, 24 h 
compared to the previously used 16 h. Additionally, commercially available 54 was used 
instead of synthesizing it. This resulted in a pure compound in high yield and didn’t 
require purification by flash chromatography as before. 1,8-dihydroxy naphthalene, 54 
(0.5 g, 3.12 mmol), and phthalic anhydride 57 (0.231 g, 1.56 mmol) are dissolved in 2 
mL of methanesulfonic acid. To this solution is added 2 mL of TFA the mixture is heated 
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and stirred at 80 °C for 24 h. The reaction mixture is cooled to room temperature and then 
poured into 100 mL of DI water. The precipitated solid is filtered and washed with DI 
water (5 × 100 mL) to give a pure grey compound which is air-dried overnight. Yield 
0.958 g, 71%. 
1H NMR (400 MHz, DMSO) δ 11.34 (s, 2H), 8.14 – 8.09 (m, 1H), 7.82-
7.75 (m, 2H), 7.62 (d, J = 8.8 Hz, 2H), 7.53 (t, J = 7.8 Hz, 2H), 7.44 (d, J = 7.5 Hz, 2H), 
7.39 (d, J = 6.8 Hz, 1H), 7.12 (d, J = 6.9 Hz, 2H), 6.75 (d, J = 8.7 Hz, 2H). 
 
1-hydroxy-3'-oxo-3'H-spiro[dibenzo[c,h]xanthene-7,1'-isobenzofuran]-13-yl 
acrylate, 51 
 
Under argon compound 51 (0.200g, 0.463mmol) and Et3N (0.129 mL, 0.925 
mmol) are dissolved in 15 mL anhydrous DCM, then acryloyl chloride (0.094 mL, 1.16 
mmol) in 5 mL DCM is added dropwise at 0
o
C. The reaction mixture is stirred at this 
temperature for 1 h, then warmed to rt and stirred overnight. The resulting mixture is 
diluted with DCM (20 mL), washed with water (20 mL ×3) and dried over anhydrous 
Na2SO4. The solvent is removed in vacuo and the target compound is isolated by flash 
column chromatography on silica gel using CH2Cl2: MeOH 98:2 for elution to yield a 
cream powder 0.128g, 57%. 
1
H NMR (400 MHz, CDCl3) δ 9.41 (s, 1H), 8.12 – 8.07 (m, 
1H), 7.80 (d, J = 7.5 Hz, 1H), 7.68 – 7.59 (m, 4H), 7.53 – 7.47 (m, 2H), 7.40 – 7.33 (m, 
2H), 7.18 – 7.12 (m, 2H), 7.00 – 6.91 (m, 2H), 6.79 (d, J = 8.7 Hz, 1H), 6.60 (dd, J = 
17.3, 1.3 Hz, 1H), 6.01 (dd, J = 10.4, 1.3 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 
169.40, 165.43, 153.80, 153.28, 147.12, 145.58, 145.19, 136.57, 135.44, 134.25, 130.12, 
129.15, 127.15, 127.06, 125.80, 125.56, 124.23, 124.08, 123.26, 122.03, 119.59, 117.84, 
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114.51, 113.39, 112.93, 112.50, 82.08. HR ESI [M+H]
+
, m/z: 487.1182 calc for 
C31H19O6
+
 487.1186. 
 
5.4.3 CTAB-mediated spectral responses of acrylate probes towards thiols general 
procedure. 
 
 The acrylate probe is added to solutions of thiols in 2.0 mM CTAB media 
buffered at pH 7.4 (phosphate buffer, 50 mM). Spectra (UV-Vis and Fluorescence) were 
collected immediately upon addition of the probe. In the case of deproteinized plasma, its 
proportion is 10% of the total volume after being mixed with the CTAB, buffer and probe 
solutions. 
5.5. Conclusion 
 Probe 52 can function as a simple new indicator for the highly selective and 
sensitive detection of GSH. This embodies a sensing mechanism that couples a conjugate 
addition reaction and a micelle-promoted 12-membered ring formation/elimination 
sequence. Due to the lack of fluorescence probes for the highly selective detection of 
GSH over other thiols in blood plasma, the discovery of 52 is highly significant. A new 
class of fluorescent probes for GSH may be developed through this new mechanism.  
We have also developed a viologen probe 24 for selective detection of GSH 
without any interference from structurally related analytes via a binding interaction. This 
probe has potential for quantifying GSH as demonstrated by the linear relationship 
between 24 and GSH concentration. 
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CHAPTER.6: TOWARDS DEVELOPING A METHOD FOR DETECTION AND 
QUANTITATION OF GSH IN WHOLE BLOOD DEPOSITED ON FILTER 
PAPER  
 
6.1 Introduction 
There is often not a clear correlation between whole blood GSH and plasma GSH 
levels. This has been seen for example in the initial phase of sepsis where plasma 
concentrations of GSH decreased, whereas GSH status in skeletal muscle and whole 
blood remain unaltered.
133
 In contrast, in another recent study investigating temporal 
changes in whole blood and plasma glutathione in hospital ICU patients with multiple 
organ failure, GSH levels from whole blood and not plasma were depleted in critically ill 
patients with chronic obstructive pulmonary disease.
134
 Levels of whole-blood 
glutathione in peritoneal dialysis patients have been used to monitor therapeutic 
outcomes.
135
 It is more efficient to use a whole blood GSH to diagnose mitochondrial 
disorders, as whole blood GSH levels are ca. 1000-fold higher than blood plasma levels.   
Moreover, it has been noted that whole blood GSH measurements generally 
minimize variability caused by sample preparation steps.
136
 In general, whole blood GSH 
levels are indicative of the pathogenesis of major diseases that are often distinct from 
those that can be monitored using plasma GSH. Therefore, there is a need to develop 
simple methods that can detect and quantify GSH in whole blood. 
The resorufin-acrylate probe though successful it has its own drawback that it’s a 
short wavelength probe, hence its efficient function in a whole blood matrix would be 
hampered by optical interferences from hemoglobin (Hb). Several years ago, extreme 
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sample dilution (e.g. 5000-fold) was used to minimize hemoglobin interference in the 
determination of GSH in dried blood spots on filter paper.
137
 Hb content would be 
reduced to less than 30 µg/mL reducing absorbance near 415 nm to about 0.25 in a 
standard 1 cm cell. Dried blood specimens on filter paper are easy to obtain and work 
with and present much fewer logistical problems as compared to using plasma or whole 
blood samples. Only a small volume of blood is required.  Disks are punched from the 
paper and the blood contents typically eluted/extracted into a small volume of solvent.  
Apart from dilution, Hb can be removed using a commercial product, 
HemogloBind. This product can isolate and remove up to 90% of blood Hb.
138
  However, 
this still requires some dilution (500-fold dilution) and even with 10 % Hb remaining 
after HemogloBind processing, there is still Hb spectral overlap.  
The work herein entails a new and relatively simple method for detection and 
quantitation of GSH in whole blood deposited on filter paper without interference from 
Hb.
124
 The method involves deproteinization of blood extracted from a filter paper with 
concomitant fractionation of GSH using size exclusion chromatography (Figure 6.1). In 
the process Hb would be completely removed from the fraction containing GSH. This 
would be an ideal method for drawing small sample volumes, which are easy to obtain 
from children and for enabling shipment of samples to a centralized lab. A small volume 
of blood dries quickly on paper as cells rupture, emptying their GSH stores. The method 
is also suitable in developing nations with limited access to refrigeration or electricity and 
in developed nations due to the rising healthcare costs and the high interest in home-
testing kits. 
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Figure 6.1. A method for detection of GSH in whole blood deposited on a filter paper
124
 
 
Another advantage of this method is that deproteinization is carried out without 
using acids and organic solvents that can adversely affect biomolecules. Compared to the 
use of acids and organic solvents, filtration is a more benign method of removing 
proteins. The use of filters may also minimize the oxidation of GSH to GSSG.
139,140
 
6.2 Results and discussion 
 We successfully managed to show proof of concept that GSH can be fractionated 
away from proteins, Hb and other potentially interfering blood components very 
efficiently from a blood spot. Upon passing the extracted GSH from the dried blood spot 
(DBS) through the PD MiniTrap™ G-25 Sephadex column, all proteins elute in fractions 
1, 2 and 3. This was confirmed by running UV-Vis absorption of the fractions and 
monitoring the peak at 290 nm (Figure 6.2).  Only fractions 1, 2 and 3 exhibited 
significant absorption responses and none was observed in fractions 4 to 6. The other 
peaks at 400 nm, and 500-600 nm are a result of Hb which is highly absorbing. It can be 
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observed that these peaks are absent in fractions 4, 5 and 6 suggesting that if GSH elutes 
in these fractions there wouldn’t be any interference from Hb. 
 
Figure 6.2. Absorption responses of DBS fractions in phosphate buffer at pH 7.4 Fractions were collected 
and immediately analyzed for absorption. 
 
Fractions 4, 5 and 6 were then tested for the presence of GSH using the resorufin-
acrylate CTAB system. Upon addition of probe 50 (2.5 μM) to the fractions in 2.0 mM 
CTAB media buffered at pH 7.4 (phosphate buffer), significant fluorescence responses 
were observed in fractions 4 and 5 indicating the presence of native GSH in blood 
(Figure 6.3). The high responses in fractions 1, 2 and 3 are a result of the reaction of the 
probe with proteins. Fraction 6 behaved in the same manner as the blank. 
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Figure 6.3 Spectral response of 50 towards various DBS fractions at pH 7.4. Fluorescence spectra (λex = 
565 nm) of 50 (2.5 μM) in solutions of DBS fractions and 2.0 mM CTAB media buffered at pH 7.4 
(phosphate buffer, 50 mM). Spectra were taken immediately upon addition of the probe.  
 
To further confirm that fractions 4 and 5 indeed contained GSH, we examined 
commercial, standard GSH and collected all the six fractions. Upon addition of the probe 
and CTAB only fractions 4 and 5 developed a pink color as well as generating a 
significant fluorescence response as shown in figure A9 (Appendix A). Other fractions 1, 
2 and 3 where proteins elute remained unchanged and their fluorescence responses were 
the same as the blank. 
To investigate the effectiveness of this gel filtration method in deproteinizing 
dried blood, control experiments were performed using human serum albumin (HSA) at 
its whole blood concentrations (60 mg/mL). As expected no responses were observed in 
fractions 1, 2 and 3, confirming the absence of proteins in these fractions (Figure 6.4). 
This effectively means that the fluorescence responses observed in fractions 4 and 5 were 
due to native GSH and not residual proteins. 
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Figure.6.4 Absorption responses of HSA fractions in phosphate buffer at pH 7.4 Fractions were collected 
and immediately analyzed for absorption. 
 
Another control experiment to rule out any interference from Hb was conducted 
using commercial Hb (20 g/dL). Hb was eluted together with proteins in fractions 1, 2 
and 3 (Figure 6.5). No absorption response to Hb was seen in fractions 4, 5 and 6.  
 
Figure 6.5 Absorption responses of Hb fractions in phosphate buffer at pH 7.4 Fractions were collected and 
immediately analyzed for absorption. 
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The same fractions were analyzed for their fluorescence response and as expected, 
upon addition of the probe and CTAB, no response was observed in fractions 4, 5 and 6 
showing that this method completely eliminated all Hb (Figure 6.6). Any shorter 
wavelength probe that can selectively detect GSH in the absence of proteins and Hb can 
be applied with this method. We selected the resorufin-acrylate probe (50) over PhCV
2+ 
(24) due to its very low detection limit and its fast response. 
 
 
Figure 6.6 Spectral response of 50 towards various Hb fractions at pH 7.4. Fluorescence spectra (λex = 565 
nm) of 50 (2.5 μM) in solutions of DBS fractions and 2.0 mM CTAB media buffered at pH 7.4 (phosphate 
buffer, 50 mM). Spectra were taken immediately upon addition of the probe.  
 
We optimized our method to increase the GSH signal from the DBS by increasing 
the drying time from 3 hours to 24 hours (overnight). Interestingly, as shown in figure 
6.7, the GSH signal increased significantly upon addition of the probe and CTAB. We 
also noticed the difference in the color of the filter papers spotted at these different times 
with the overnight filter paper looking completely dry. This was attributed to the 
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complete rupture of the erythrocytes empting more GSH stores. For further studies, a 
drying time of 24 hours was used. 
 
Figure 6.7 Spectral response of 50 towards various DBS fractions at pH 7.4. Fluorescence spectra (λex = 
565 nm) of 50 (2.5 μM) in solutions of DBS fractions from blood dried at different times and 2.0 mM 
CTAB media buffered at pH 7.4 (phosphate buffer, 50 mM). Spectra were taken immediately upon addition 
of the probe. (a) Blood dried for 3 h (b) Blood dried for 24 h. 
 
Having identified the optimal conditions for GSH detection without any 
interference from proteins, Hb and other blood components, we investigated the potential 
of this method in quantifying GSH. The fluorescence response of 50-CTAB system 
towards fractionated GSH increased linearly with incremental addition of GSH over a 
physiological relevant range (0-2 mM) (Figure 6.8 (a) and (b)). The concentration of 
GSH in a DBS of pig blood was determined to be 1.825 mM by standard addition which 
falls within the range of reported intracellular GSH levels (1-2 mM). 
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Figure 6.8 Spectral response of 50 towards DBS spiked with various concentrations of GSH. (a). 
Fluorescence spectra (λex = 565 nm) of 50 with increasing spiked GSH concentration (0-2 mM). (b) 
Calibration curve for 50 showing linearity between fluorescence intensity and spiked DBS with GSH. All 
solutions contained 50 (2.5 μM), 2.0 mM CTAB media and 50 mM phosphate buffer (pH 7.4). 
 
During to the spotting and filtration process some GSH is lost. We evaluated this 
by comparing the fluorescence responses of standard GSH that underwent the entire 
process of spotting, extraction, reduction and filtration against one which didn’t undergo 
the process. As shown in figure 6.9, more than 70% of native GSH from the DBS is 
recovered in this method, however the process can be optimized to reduce the losses. 
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Figure 6.9 Comparison of commercial GSH fractions vs non-fractionated GSH at pH 7.4. Fluorescence 
spectra (λex = 565 nm) of 50 (2.5 μM) in solutions of GSH fractions from commercial GSH (spotted, dried, 
extracted, reduced and separated by the column) and 2.0 mM CTAB media buffered at pH 7.4 (phosphate 
buffer, 50 mM). Spectra were taken immediately upon addition of the probe.  
 
6.3 Experimental section 
6.3.1 Fractionation of GSH 
In this method blood is spotted on the filter paper and dried overnight, followed 
by extraction with buffer. Upon drying blood, cells are ruptured releasing GSH which in 
turn becomes oxidized to GSSG. Once oxidized, it is stable in dried blood specimens and 
can be assayed at a later time. In this assay the oxidized glutathione (GSSG) is reduced to 
GSH by treating it with the immobilized tris(2-carboxyethyl)phosphine (TCEP gel), a 
disulfide reducing agent. The reduced sample is passed through the PD MiniTrap™ G-25 
Sephadex column where GSH is fractionated away from proteins, Hb and other 
potentially interfering blood components.  
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6.3.2 CTAB-mediated spectral responses of acrylate probes to GSH fractions. 
 The acrylate probe is added to fractionated solutions in 2.0 mM CTAB media 
buffered at pH 7.4 (phosphate buffer, 50 mM). Spectra (UV-Vis and Fluorescence) were 
collected immediately upon addition of the probe.  
6.4 Conclusion 
We have developed a new separation technique wherein glutathione can be 
fractionated away from proteins and other potentially interfering blood components very 
efficiently. This method eliminates the need to use very expensive materials like 
hemoglobind to remove Hb and allows for the use of shorter wavelengths probes to 
determine GSH in natural media. This assay has potential for quantitation of GSH in 
whole blood as demonstrated by the linear calibration curve.  
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APPENDIX A: SUPPORTING INFORMATION 
 
Figure A1. Spectral response of MV
2+
 towards various spiked thiols in human blood plasma upon 
irradiation. Absorption spectra of solutions of MV
2+
 (50 mM) in human blood plasma and 0.5 M Tris buffer 
(pH 7.0) spiked with 1.5 μM Hcy, 25 μM Cys and 0.6 μM GSH. Plasma (10% v/v) was added to an argon-
saturated solution of viologen, thiol and buffer and irradiated for 15 min using a Reptisun™ lamp. 
 
Figure A2. Spectral response of BV
2+
 towards various spiked thiols in reduced human blood plasma upon 
irradiation. Absorption spectra of solutions of BV
2+
 (20 mM) in reduced human blood plasma and 0.5 M 
Tris buffer (pH 7.0) spiked with 1.5 μM Hcy, 25 μM Cys and 0.6 μM GSH. Plasma was incubated for 1 h 
with TCEP Gel and centrifuged at 1000 rpm for 5 min. The reduced, filtered plasma (10% v/v) was added 
to an argon-saturated solution of viologen, thiol and buffer and irradiated for 15 min using a Reptisun™ 
lamp. 
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Figure A3. Spectral response of BV
2+
 towards various spiked thiols in reduced human plasma upon 
irradiation. Absorption spectra of solutions of BV
2+
 (20 mM) in reduced human blood plasma and 0.5 M 
Tris buffer (pH 7.0) spiked with increasing concentrations of thiols. Plasma was incubated for 1 h with 
TCEP Gel followed by centrifugation at 1000 rpm for 5 min. The reduced plasma (10% v/v) was added to 
an argon-saturated solution of viologen, thiol and buffer and irradiated for 15 min using a Reptisun™ lamp. 
 
 
Figure A.4 Spectral response of ACNV
2+
 (26) towards various amino thiols at pH 8. Absorption spectra of 
solutions of ACNV
2+
 (350 μM) in thiol solutions (15 μM Hcy, 250 μM Cys and 6 μM GSH) buffered at pH 
8 (Phosphate buffer (80 mM) at 10 min. 
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Figure A.5 Cyclic voltammograms of current vs potential of asymmetric viologens and methyl viologen (4 
mM) in phosphate buffer at 50 mV/s. 
 
 
 
 
Figure A.6 Cyclic voltammograms of current vs potential of 24 and 25 (4 mM) in phosphate buffer at 100 
mV/s. 
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Figure A.7 Cyclic voltammograms of current vs potential of 23 and 25 (4 mM) in phosphate buffer at 10 
mV/s. 
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Figure A.8 Spectral response of PhCV
2+
 (24) towards various amino thiols at pH 9. Absorption spectra of 
solutions of PhCV
2+
 (500 μM) in thiol solutions (500 μM) buffered at pH 9 (Tris buffer (200 mM).  
 
 
 
Figure A9 Spectral response of 50 towards various commercial GSH fractions at pH 7.4. Fluorescence 
spectra (λex = 565 nm) of 50 (2.5 μM) in solutions of GSH fractions and 2.0 mM CTAB media buffered at 
pH 7.4 (phosphate buffer, 50 mM). Spectra were taken immediately upon addition of the probe.  
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
350 450 550 650 750
A
b
so
rb
an
ce
 
Wavelength (nm) 
Blank
Hcy
Cys
GSH
0
100
200
300
400
500
600
700
800
570 590 610 630 650
F
lu
o
re
sc
en
ce
 I
n
te
n
si
ty
 (
a.
u
.)
 
Wavelength (nm) 
Probe only
F1
F2
F3
F4
F5
F6
117 
 
APPENDIX B: CHARACTERIZATION OF COMPOUNDS 
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